<SEC-DOCUMENT>0001193125-11-315665.txt : 20111117
<SEC-HEADER>0001193125-11-315665.hdr.sgml : 20111117
<ACCEPTANCE-DATETIME>20111117161155
ACCESSION NUMBER:		0001193125-11-315665
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20111116
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20111117
DATE AS OF CHANGE:		20111117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		111213183

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d257477d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): November&nbsp;17, 2011 (November 16, 2011) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;8 &#151; Other Events </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;16, 2011, ARCA biopharma,
Inc. issued a press release announcing that Gencaro&#153; demonstrated 74% risk reduction for new onset atrial fibrillation in heart failure patients with genotype believed to be found in nearly 50% of population. The press release is furnished as
Exhibit&nbsp;99.1 hereto, the contents of which are incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial Statements and
Exhibits </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Gencaro&#153; Demonstrated 74% Risk Reduction For New Onset Atrial Fibrillation In Heart Failure Patients With Genotype Believed To Be
Found In Nearly 50% Of Population,&#148; dated November 16, 2011.</FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: November&nbsp;17, 2011 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;Patrick M. Wheeler</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:&nbsp;&nbsp;&nbsp;&nbsp;Patrick M. Wheeler</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX TO EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Gencaro&#153; Demonstrated 74% Risk Reduction For New Onset Atrial Fibrillation In Heart Failure Patients With Genotype Believed To Be
Found In Nearly 50% Of Population,&#148; dated November 16, 2011.</FONT></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d257477dex991.htm
<DESCRIPTION>PRESS RELEASE DATED NOVEMBER 16, 2011
<TEXT>
<HTML><HEAD>
<TITLE>Press Release dated November 16, 2011</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">


<IMG SRC="g257477g32r27.jpg" ALT="LOGO">
 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com
</U></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GENCARO<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> DEMONSTRATED 74% RISK REDUCTION FOR NEW ONSET </FONT></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ATRIAL FIBRILLATION IN HEART FAILURE PATIENTS WITH GENOTYPE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>BELIEVED TO BE FOUND IN NEARLY 50% OF POPULATION </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:78%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Data
Selected for Oral Presentation at American Heart Association Scientific Sessions 2011 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:89%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gencaro
Potentially The First Genetically-Targeted Treatment For Prevention Of Atrial </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fibrillation </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, November&nbsp;16, 2011</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing
genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced results of analyses of atrial fibrillation and pharmacogenetic data from the BEST trial, a previously conducted Phase 3 heart failure trial
involving Gencaro in 2,708 advanced heart failure patients. Pursuant to their analysis, researchers concluded that Gencaro substantially decreased the risk of new onset atrial fibrillation in a large moderate-to-severe heart failure population, with
a risk reduction of 41%. Furthermore, the researchers concluded that patients with a specific genotype (homozygous arginine at beta-1 389) had a 74% risk reduction for new onset atrial fibrillation. Based on a DNA sub-study in the BEST trial, ARCA
believes approximately 50% of U.S. population has this specific genotype. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The data were selected for oral presentation at the
American Heart Association&#146;s Scientific Sessions 2011, being held November&nbsp;12-16, 2011 in Orlando, Florida. Dr.&nbsp;Ryan Aleong, Assistant Professor of Medicine, Cardiology, Director of Implanted Cardiac Device Clinic, University of
Colorado Hospital, and Interim Director of Arrhythmia Services at Denver Health Medical Center, presented the abstract &#147;Prevention of Atrial Fibrillation by Bucindolol is Completely Dependent on the Beta-1 389 Arg/Gly Adrenergic Receptor
Polymorphism.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Data presented in the abstract included: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beta blockers have modest efficacy for the prevention of atrial fibrillation in chronic heart failure/reduced ejection fraction (HFREF)
populations, with risk reductions on the order of 20-40%. The researchers assessed the ability of the beta-blocker/sympatholytic agent Gencaro to prevent atrial fibrillation in the BEST trial, identifying new onset atrial fibrillation from adverse
event/serious adverse event (AE/SAE) case report forms as well as routinely measured electrocardiograms (ECGs) in patients not in atrial fibrillation on study entry, and constructing </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Kaplan Meier curves using Cox regression. In the entire 2,708 patient cohort there were 115/1190 (9.7%)&nbsp;new onset atrial fibrillation episodes in baseline sinus rhythm patients in the
placebo group, and 75/1202 (6.2%)&nbsp;in the Gencaro group. The time to event hazard ratio (95% CIs) was 0.59 (0.44, 0.79), p = 0.0004. In the 1,040 patient DNA substudy based on 80 total events the hazard ratio was 0.57 (0.36, 0.90), p = 0.014)
and the therapeutic effect was completely dependent on the beta-1 389 Arginine/Glycine polymorphism. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">


<IMG SRC="g257477g82h53.jpg" ALT="LOGO">
 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conclusions from the analysis included: 1) Gencaro produced substantial prevention of atrial
fibrillation in the entire BEST population, with a risk reduction of 41%; 2) the risk reduction for new onset atrial fibrillation was pharmacogenetically determined, with patients who were homozygous arginine at beta-1 389 having a 74% risk
reduction and patients having any glycine at this position having no effect. This effect differentiation is greater than for heart failure mortality or hospitalization endpoints, where the homozygous arginine at beta-1 389 genotype is associated
with risk reductions of 34-48% vs. 8-22% in the glycine at any position genotypes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Atrial Fibrillation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Atrial fibrillation is a disorder in which the normally regular and coordinated contraction pattern of the heart&#146;s two small upper
chambers (the atria) becomes irregular and uncoordinated. The irregular contraction pattern associated with atrial fibrillation causes blood to pool in the atria, predisposing the formation of clots. These clots may travel from the heart and become
lodged in the arteries leading to the brain and other organs, thereby blocking necessary blood flow and potentially resulting in stroke. In addition, in patients with heart failure with reduced left ventricular ejection fraction (HFREF), new onset
atrial fibrillation may also contribute to worsening heart failure and increased risk of death. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Studies estimate atrial
fibrillation affected between 2 and 3&nbsp;million Americans in 2005. Those same studies estimate the prevalence of atrial fibrillation will likely increase to between 3.8&nbsp;million and 4.8&nbsp;million by 2025. Industry estimates expect the
atrial fibrillation drug market in developed countries to increase more than eight-fold, from $843 million in 2009 to $6.8 billion in 2019. The Company believes there is an unmet medical need for new atrial fibrillation treatments that have fewer
side effects than currently available therapies and are more effective, particularly in patients with HFREF, where most of the approved atrial fibrillation drugs are </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
contra-indicated or have warnings in their prescribing information. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA
biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular
diseases. The Company&#146;s lead product candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational, pharmacologically-unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation in patients with heart failure.
ARCA has identified common genetic variations in the cardiovascular system that it believes interact with Gencaro&#146;s pharmacology and may predict individual patient response to Gencaro, giving it the potential to be the first
genetically-targeted treatment for the prevention of atrial fibrillation. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit <U>www.arcabiopharma.com</U>.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release may contain &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are
not limited to, the ability of genetic variations to predict individual patient response to Gencaro; the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment; the projected increase in prevalence of
atrial fibrillation; and, the projected increase in the size of the atrial fibrillation drug market in developed countries. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and
performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether
they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the regulatory
approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual
report on Form 10-K for the year ended December&nbsp;31, 2010 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g257477g32r27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g257477g32r27.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#D`U@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/:M4U-K9Q#!CS.I)'2OFLWS>>&E[&A\75]CKH4%-<TMC/34
MK]NL_P#XZ/\`"O+H8_,JNKJ6^2_R.AT:2Z%A;R^P/W__`(Z/\*]2%?&VUG^"
M_P`C-TZ?84W=\#CSCG_<'^%:2JXQ.W/^"_R$H4NQ`^H7Z])__'5_PKS:V+S&
M&L:GX+_(T5*D^A-8ZQ-YZQW)#*QQNQC%&`SNNJRIXG5/K:UON)JX:/+>!NU]
MF>>%`!0!SLOBN"/Q.NE87R_NM)GH_I0!T5`!0!EZC?:G9^8]OIB7$*#.1/M;
M\L4`85EXWGU&Z2VM-),DS?PF;`'XXH`V)M1UJ"(R'1D<#DA+D$C\,<T`1:1X
MLL-6G^S8>WN>GER<9/H#0!O4`4=2U>QTB'S;R<1@_=7JS?04`9=KX@U#5OGT
MS2CY'::X?:#]`.M`%MF\0J-PCT]_]D,X/YT`91\67MIJ<-CJ.E>0TKA0XDR.
M3C(XYH`ZR@`H`R/$6N)H6GB;:'E8X1">M`%W3;Z/4M/ANXONR+G&>A[B@"U0
M`4`<OJI_XF\H]E_E7PN84E/,9W\OR/4H.U)$MK%O(V[3_LDXKUL+05M")RT+
MC/!$Q@`+MP<?W3Z5W\U.+]FE=_D86D]2R8U=69DV;^"W7%=+BI7;5KF:;10N
M[<1^BCW/)KS\1021T4YF6_$Z?45\QB:"5127<ZD]#L%^XOTK]!A\*/(>XM4(
MRO$6K#1M(DN%P9F^2)?5STH`\_\`$N@S:-IUEJ.YC<.<SL3DASS0!W_AO5UU
MK18+D']X!MD'HPH`UJ`(KG_CTF_W#_*@#R[P!+N\4LO_`$S?^=`'JI(52S$`
M#DD]J`/(T235?&[_`-F(607&[<O0`'DYH`]3U"]33M.GNY.5B0MCU]J`/,M`
M2;Q=XG:>^8O$GSN.V.R^PH`]51%C1410JJ,``8`%`#J`*6IZ7!JML(9P1M8.
MK#JI![4`7%&U0,YP*``D*"2<`=:`.$GLW\8MJ5\"1!;@Q6?/!8=6H`K_``\U
MHI<3:1<';G+1@]CW']:`/1*`"@#D]7DVZU,/9?Y5\3CI*.83^7Y'JT%>BBS9
M7"+C<8P/]S)KU\+5270QJ1?09<)/;7;R!&:-OF!`SCZ^E<T_:X:JVU>+Z_Y]
MBH\LXVZEF&\GN0(T1MI[G@?G7=3Q,JJM%&<J<8ZL=>SJ!L!3<HP0Z8/YU=>:
M2M^@J<7N8CRYG3I]X5\SB:B<UZG;&-D=JOW%^E?=P^%'CO<6J$>?W$U]XI\7
M.=.,)M-);`\[.QG_``ZT`:VJ:;XDU739[*X;36CD7'"OG\*`.-\!:S)HWB2;
M1[QMB3,4(/`5Q_CTH`]<H`AO/^/*?_KFW\J`/&?`L1O_`!08!<S0'8YWPMM;
MK0!K>.;#7-'"S'4[J\TUSR)'^Z?1L=J`.N\$:KI6IZ0!I]O%:S1\30H`"#Z^
MXH`N^+K:2Z\+WR19W+'OP.^.:`.!^%NH1+K-U:NV))HP4'TZT`>LT`%`!0`@
M(894@CU%`'+>-M6EM[.#2;$YO]1?RD`ZA>YH`73=-\2:7IT%G;MI@CB7'*OD
M^Y]Z`.`\36^I>&?$<.I3")7E?S08`=I/<<T`>NZ7J$6J:9;WL)!29`W'8]Q0
M!;H`X[Q)%)#JAF8'RY`-I[<"OA,[I5*6+=3HSU\)).GR]C/AO3$V0>?Y5CA\
M9RFTJ=S0BU8I%L#G+'+'/6O6AC[1M?U.=T$W<EFUD/)*"?D?MZ5K4S!-OLR8
MT+)&=/J!D`!;..A->77QMU:YT1IV&6227E]%'&"6W`GV'K7G4(U,57C&*ZES
M:A!MG?@8`'I7Z4E96/!.#\5^/K>+2Y[;1%GNKQ\Q[XXFVQ^ISCK3`=\.]3TJ
MVT6VTP/)'J+DO*DL;`LQZX)'(H`[6ZN8;*VDN+A]D48RS8S@4`>'^-[B"]\3
MKJ6@K<2A@&=UA8`..A''-`'H?A_X@6%[:VT&I)/97S`(5DB;:S>H;%`&AK_B
MS2M,2YLY))9+ORR/)BA9CDCV&*`/)O!6H2:%XF6]OK.Z%NRLK%8F.W)ZXQ0!
M[-:ZAI/BG39XX'%Q;L-DBLA7&?8B@#R'4]/UCX?^+$ET]998'.8BJDAU[JV*
M`/2M*\>:3J2PQ3I<6ES+A?+F@8#=Z`XP:`.9\2>`-1T_4QK7A9SYBOYAM\X*
MGOM]1[4`;.D_$.VVK;>(;6?2KY>&\R)MC>X../QH`VW\8^'(TWG6;4CT5]Q_
M(<T`<?XE\?76I6SZ?X8L+N=I1L:Y\E@`#_=&/UH`Z2+5],\(:'8V%X\OGK`&
M$21L[L>_0>N:`.*T+Q'#=>-[K7->AN+:,)LM0T+,J#WP.#0!ZS!-'<P)-$VZ
M-P&4XQD4`>?_`!(U+2;_`$>;3XY))=3@8-'''$QP>^3C`&*`,+P!XNET""33
M]6M+I;,MNCE$3$1^H(QTH`]7T[4K35;-;JRE\V%NC8(_0T`33V\5S$8IHU=#
MV(K*K1IUH\E171492@[Q9D/X5TYF)7S5]@_`KQY9#A).ZNOF=2QM1#?^$4L!
M_'-_WU2_L+#KJ_O']=J=D'_"*V']^;_OJG_86'_F?WA]=J=D*/"FG@\M,?\`
M@5)9!A;ZM_?_`,`/KM3R-.ST^UL$VV\03U/<_C7J8?"4<,K4HV.:I5G4=Y,L
MUU&93U#4[32H!-=R;$)P."<F@"S#*)X4E564.,@,,&@"&]O[;3H/.NI1%'D+
MD^M`%A&5T5U.589!]10`M`!0`4`07=W!8V[7%P^R)>IQG%`"6-[%J%HES!N\
MM\[2PQF@"Q0`4`->-)$*2(KJ>S#(H`B6RM$;<MK"I'<(!0!/0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`<9K5W-K'B6#3+.'SXK0[Y03A=W8-["@#7\/:K=ZD
M]\ES'"%MY?+1X<[6]<9]*`*]UK-Y+XDBTF"SB:,?-+YGS$+Z\<"@"]K.M)I0
M@ABB,UW<-LAB!QD^I]!0!7MM8NH_$4>D78BD>2`REH@0(S_=-`$7BS5+JTB@
ML+-<7%ZWEHX;D>N!0`S2]2O;37QH%VZ7'EP"03*"&_')H`B\;7SK;6VEP*SS
M7C@%%ZE1UH`?%J>HZ?K6G:3)!;B&:,D(A.Y`/4]#0!MW^I16)CCVF6XEXBA3
M[S?X#WH`R(]9U*X\1IIL26^R,;[AERWEC^[GUH`F\4:Y<:)9++!%&2QVAI#W
M]`!0!+IUQKES);37%O;0VKIEUW'S`?Y4`4_$?B*\TJZ@MK2U6265@%#'+./8
M#^9H`K'Q+J@UXV"VUN^V/=*%8XA_WFH`T?#6K7NKPW$UQ'&(5DVQ2("`^.O6
M@"W/JRBZ>UM%666,9E8G"1#_`&CZ^U`%3P_JM[J\MU/((OL:-Y<3(I^<CJ1G
MM0!NT`%`!0`4`%`!0`4`%`!0!S-AX7NK);F$:F1#<2%Y&2+$K`]MV>!^%`&]
M:6<%C:+;6J"*-!A0/Y^]`&1HWAR73K^XO;C4'N)9GW'"[0?KZ_3I0!8U+13=
MZM9ZG!*J7-LK*HD7<I!]LB@`TO18],GN+ZXN#<7D_P#K)G&T`>@'84`<_8&X
M\1^*KK5+:6,6]C^Y@WKN5CW/7K0!T>EZ,EA//=RS&XO;@_O)F&/P4=A0!7GT
M&9]5N=4BO0+IXQ'!NBRL/J<9YH`M6&D_9[I[VZF^TWSJ%,FW:%'HH[4`4KCP
M_=2Z])J4>IM$KQ^7M$8+*/8GI0`WP]X8;0WE=[YYV=BW"[<Y_O>M`%J_T-=2
MU>TO+BX)AM<E8-O!;U)S_2@#7H`Q8]`*ZO=:I+=>;=2+LA+1\0#V&>?TH`I?
M\(DT>A7%C!?E;JY?=/=-'DOSR,9X'XT`;&E:8NE:>EJLK/M&,G@#Z#M0!@#P
M=>?V9=V3:RVV=RY(CQDG^\<Y-`&[HVEC2-/2V\]I2H`R1@#Z#M0!HT`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
#'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g257477g82h53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g257477g82h53.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`-,!I0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?Z`"@`H`\EO_BGJ]G\3)]!6ULO[,AU*ULBSQ.K[948LQEW
M;`05X4C+#..A-`'=>)_$O_".BSQ%;3/<2A%AENA%))E@"(EVDR-\P^7CZTE=
MS4$M_P"KV[+=OHN_0E>-.4[;?Y7MZOH96K^/SI.NWE@^F"2.UC>1R)R)MJQ[
M_,\LICRL_)OW'YLC'!HBVTW_`)VW2U=M-[]?=3?>RDVFDDW^;T;T[[6Z:_*^
MGX9\66WB#3;ZZ+6J"QF,4TEM<B>`X57W))A=PPPSP,$$=LU52U.FJDMM?P;7
MZ#C>4N5>7XC-,\96EQI,U[J41TYH)DB>(DR,#(%,709RP=>,<$D<XS0TXI<V
M^NVNJO=>?EIKIH)OJMMT^Z>E_)7[[6UT+D/BG2I]633(WNOM39QNLIE0$*&(
M+E-H(!&03D9QUXI=_*_X.SMWU[!=63_K777L[:V?34R4\:O''I\TUI&UO>2L
MQE1\"&!I1'"Y'.XL64]N-Q[8)!-M1>]E?H[M-I6^5GY]-=*DK<UELWIY1^)]
MM-^[7F:]SXITBUENXGGF=[1UCF6*VED*NVW:HVJ<L=ZG`R<'/8TD[[?UO^5G
M?MUW1-TG9_UM^=].[T6I6@\407^IZ7#8$FWNH)[EVF@>-@D95.%8`@[G'4=`
M?7-4E[KG]E)/?OJOE9/\!M;);WM^=_QL7-*\1Z7K0D.GSO+Y<:2G,$B;D<$J
MR[@-P.#R,],42BXIMK9M?-?U\^@D[VMU_K_A^W4ETS6;75O-^S17L?EXW?:K
M&:WSG/3S%7/3MG%%M+C*;>(E/BM-%BMM\8C8RW'F`!'`#;-N.3M8$G(QD=<G
M$*2;:?9O[K7_`#^]-=!R3BHOO_P;?DS*?QS(=)U74;?2?-@LI$\LFX`$L3`$
M2'@X!'0#.<C.,G!&2=KZ7DH^E^6WS]Y76EK,53]WS7Z)O[KW7WJUSI[?4;6[
MGNX()-\MFXCF7:1M8J&`R>#PP/'K3OIS+^K#LU:_57_K[CBY/B9!%!*633`3
M>"U@N/[3'V1LH7.^;9A&`!!4!N2HSSD$;M*^F_W*VJ[J[LM.C[,&N63BUM;\
M6U;R:M=G7S:M;6>D1ZC=R*(F53FWW3!BV,!-HR^2>,#)]*J?NRY?TU^[\^Q$
M9<T>;3[]/O\`R[E*#QAH-S&SQ7^=K1HRF)PRL[%5!4C(^96!R/E*MG&#1:VK
M_JT>;_TG4;DD[/\`K6WYZ6].Z(E\;Z`Z96ZF+%@JQ_9)O,DRK,"B;=S*0C$,
MH(.TX)Q2LU'FL_N]-^UKJ_8+K2W];]?E_5T"^-=&:[EA5[DQQV*7_P!H%M(8
MC$V<88#KQTZGH,D$`U4I1>Z:7S?;O_7F4U:*D]+WWTM;>]]OGMUMI>6^UQXH
M-(O+6)OLEU=I!,)X'CD56#!2%;!4[]O4=,^U-:34'UO^"O\`DFO6Q#DE!R[6
M_%I?K<W*104`%`!0`4`%`!0!'<3"WMI9B,B-"Q`[X&:`/+OAC\3=8\8ZNEEJ
MMO91+-8-=HT,3PD,)FCV@.Q\P87.Y>`<@\B@#J]4\9'3M>N-,BLHKUH;62<Q
MVUSYERI501NA"DJK9`!R221QS4)MJ3MHNO3=+5].KZZ)OR')./+IO_DWI]UN
MFNGF9Q^(VW04U%[;3D\RZ:WBF?4=MG(%3<6$YC^J@;?O`CWJY^Y;T;^YVT[W
MT:[K4F#<F].J_%7U[6V>^MEUTUIO%R/H6CW]A9^=/JZJ]O#/+Y2H"AD9I'PV
MT*H.2`><#O558^RJ2@VO=NV]M%;7\5]^H0:<;OT]7V_7T3W>CKZ/XZL]0NI(
M+AK1$58`MQ:7?VF&225Y$55<*.\>,G'+8P.]<EXJ2ZMK[DF_U^[OH)RY=_ZU
MM_P_;TU-J3Q#ID6DG5'N&^R"0Q!A$Y9WW[-JJ!N8EN!@'/;-9]FM;V:MKHU?
MIY:^2W*6M[=+_AO_`)>I';^)M-N;Y+,?;(IWC,B"XL9X58``D!G0`D`\KG(Y
MXX-)M*_DK_+^F@ZI=]/G_2(H?%VC72VOV6YDE:[0R6X^SR@2*-N6'R_=^=?F
MZ<T2]U/R_P"#_E\]+;J\QDG;S\O3_/\`/L[1Z5XQTC4Q9QK<@3W,*R#9'*8B
M2@?:LC(H+;3G;PV.2HYK2I'DE)?RW_!V_/32^N@XN]OZ_P"&^9-:^*](O39"
MUEN)A>C=`R6<Q5EX^8G;@+\P^8X'OP:E)WM_77\[.W?H3SQM?^NG3?2^O;K8
MK?\`"6VL&HZE%=N4AM[D6D*Q0/+))((1*X`4$GY3P`/X319J',^MW\DU'7YW
M^5GW+EI*WDOO=_T2^>AH3:_80Z9;:BOVFXM;D!HFM;.6<D$9!*QJ2!CN0*))
MQERO<%JKD&M^(8])T$:C%;O/+*N;>W?,+2':6P=PRN%!)R,@`\9XK.K+V2=^
ME_PU>WX=+V5]2Z<>?;^NB_$S+3QI)=>*H=&&G(BR)O9C.?-5?+W^9Y>S!BR=
MF\-][C'!K51UE?I?\&EKV;O==TO6V'.VHM+>WXIO3O;9[?E>SI/C&TU*ZDBE
MB^SQR7*P6;[B_P!I!0N&X&%!56(R>F.A.*SA+F]>WR3_`">J[FTHN,FNBM^=
MOS5O^`6-4\1+I^N:?ID=MY[W#@3/Y@40*=VTD8.22IP./NGG@`G,N;E?]:-_
MDM>UUW%)-0YOZW2_5!H/B-=<;4'%N(+:V<>5*9`WG1E<A^GR@]1R>,'CH!23
MBY/2W^2?Y/7LPDG&?)_6[7YH2U\9:#=W"01WK)*^=BS021%@%+;AN494JK$,
M.#M."<&F](N3T23;\K6O?M:ZTWU)NFTEUV_'_+?;[T1GQQX>1=[WSQQ^3YWF
M/;RJF-F\C<5QO"?,4SN`R<<5IR2YG"VJT_&WSU=KK2XE.+CS)W7_``+_`):K
MOTW"7QII$;VJ*+V5KB\^Q;4LY=T<FS?\RE00,8.<<@YZ9(A:N*[W_#\B[>[*
M7:WXZ:=_7;IOH-NO%$9EM&L%>2W^WK:7+26TB#YMR@QLP`;#A02,C&?:B.KB
MK?%>WR7-?T:7XK4B4HQC)]K?BTOO77JK6L='04%`!0`4`>32?"B3Q!XY\1WV
MOR2QZ-<7MM<P01.F+DQQL,OP64#>RX!&<GV-`'73:%>>)=/NK'6+O5+6T\^1
M&A;[-BZA+`C)16(7'`P5;'7GFE%64)/=6?S3NOTOT&VTVE_5U_PY-+X,MGU>
M348]2O8',S7"1H(2L4S1>7Y@+1EB=O9B5]JJ+<59/NODWS/\26ET\OG;1>GR
MM^+O8C\+6JZ'?Z9+=W4_]H,SW5S(4\V8L`#G"A1\H"X"C@?C0]5%=%T^=^O=
M[^NE@UNVG9OKVTMIVMT\]2L/`>A0SR/8V_\`9\4CV\C06B)%$7AD\Q6VA>I/
M!/<`>F:J%24'IY_BK/\`#\0<4U:W2WZ_A^K,6X\'^(#XHU?4;.>P@2^1X_/(
M5I=C*`!_J@ZD$9YE9>,;1D;<H1M!TYZIO77^]?\`]);7Y-(N4GS*4=UM?;;\
MK]K?>;.H>`?#^J+/]LLTE=[9+:&1HT+VJJ"`8F*Y0\YSZXJ^9\SDGK>]_N_#
M3\69QBHI1>L4K6Z?T]GZ(K^(/!\EWHFHVNGR+--?W<=S,MVR[6VJB$<QNO2,
M'YD89STX(51N?(ND;_CS/\W_`$]2H^ZG9ZV2^ZWYK^K$VE^&[ZU;1)[N6V:X
ML[.6SF$*A%$;E2H4!0"5\M1]U0>2`.E5.3GS)[22OWNNOIK+OT$FXI66SO\`
M+7_@%[1_"]CHK1FW>:01V$-@!*5(,<6[:3@#D[CGM["BI+VDIRE]IW92=HQB
MNE_QM_D6],T+1]$\W^RM*LK#S<>9]EMTBWXSC.T#.,G\Z5W:W05NIG2>"M'D
MUDZI_IBS,9#)&M[*(G+KM8E-V!P.P'Z"L?90LXO9IK[W=^>_];#OK=;W3^Y6
M7X?U8I/\/--6PO;*SU'5;2&]V"4"[,WRH,!1YP?`Z=.>`,XXJ[7=WWYOFK6_
M%?/K=6)Y8\O+;2UOE_3M^6IO:=ILUD+DRZE<W<DS*0\I'R80+PH&T9QN.``2
M3Q5O566F_P#6M]BK[>7]:_?]UET,0^!86NI+]];U-M5=T87Q\D2*%5E"A1'Y
M>,2/U4GGKP,2M$XK9WOYW27_`+:MK;>HGK9OIMY?U<OW_A/2]0\,1>'Y8R+*
M%8UBR%<KLQM.'#*W3HP(/I3J?O)<[WO?]/RT_P"".[UOUW_/IY_U8H6_P]T6
MWO-,N092;")XEC18XHI0V[ETC15R-[XP!C<?6B24N;F5^9)?=V^6GIIL).22
M2>SO^6GI=)_)#-'^'>C:'-;R6C.OV>;SHPL$$?\`RS>,!C'&I<`2-RQ)SWZY
MM3ER.#ZIK[[/;;HNGZ6GE2V\OP_'\2Q!X*L[2V2WMKZ[CC&GKIS`B)P\:D[2
MP=""1N;M@YY!XK)QO==[?A_GL_PLS9U)-I]FW\W_`,,K`GA066E:+I-A,?L5
MC>"XE,I`=E!9P%"J%'SE>```HXZ`5HY<TXS?1?\`MO+K\G?U,/9QY)0[N_\`
MY,I=O*WXWOOTU26%`!0`4`%`!0`4`07D336-Q$GWGC91GU(H`\A\(?##4/#6
MBZ3KEY]NG\26$)AAL[9[<K`C3,S*"^`Q*N^26_C;!X7`OBCVNK^G7^D'1^AW
M^M>#+7Q%<F;5-0OI80CB&V_=".`NFPLN$W,<$\,6')XZ4DN67,GKW^:E^<4%
M[JSV[?*WKUZ,?'X3,-A=6\.NZE%/>3&:YNT$`EE.P)@_NMH&%'*J#QUJG:24
M6M%?3O=W?G]S0)N+OZ?*W]=;_=H6KOPU93Z=I]G;/-8G3BILYK<C?!A2G&X,
M#\I*X8'@^M.4I2FYMZO?SN$$H1Y-U_6OJ84_P]AM]!UVWT^]N)M1U.#;Y]U(
MJ[91))(LF8T&TAY">!V&!4RM*G&ELD[_`)7Z^6WRV+4_?YY=K?*UOR-M_#-H
M_ANRT5)9H([-8O(FB8>9&T>"K#<""<CN"#SD&JF^:?.M.VVFC5ON=OR,HI\M
MIZWWOU>]_6^IGV?P_P!,L_$+:X;J[GO6+,7F\MFRR;6^?9O(/7:6VC`V@#BI
MLK.*ZIK[W?YO3=W86NXMN]G?\+?)>2LKFA8^%[+3_P"S/*EG/]G6#:?%N8?-
M&=F2W'WOW:],#D\5I5J.KSW^WJ_QV^]CBN6UNFIEZ-\-]$T+4(+VSW^9#"(1
MYD$#,<1B/=YGE^8#M'0,!UXY-3.3ES_WK_B[O\>]_P`K"5FFNG]?U:WYEIO!
M.GO%H$)N;CRM#6,6XVQ%FV;<$N4WC.T9V%0>A!'%5*I*5:59[N_IK>_Y_@A.
M-Z?L^E[_`'._]=?,='X5C_M^?4))"(_M@OH@C<^8;<P,&!'3;@C!Z_K*DU!P
M?9KY-J7WWO\`(J3O+[OO5_TL68O"FBC0;'1KRP@U&SLD5(A>Q)+C`P#R,9QW
M`J=[>6@W)MM]VW]X:MX5TG6+""RFBE@AMD,<`M)WM_*4KMP-A`QCC!R/:HJ1
M]HVY;M-??:^^^RW"+Y;:;._S_ILS+/X>Z797*,MY?RVR.THMII5<>8T7E%S(
M5\TG9QR^!V`P,:2?/%QEJFFODW=_B3%<MN7R^=MM]OE;\7>SIW@NQT>^6?3[
MW4(H_,1WADO9958(A14^=C\O.<<]!V&*4=&V];W?S=E^G]60TE%<J71+T2=]
M.W;TNK:L=K/@G1M<OOMET;U)BRE_L]]-$LFT$`%58#H3R`#[UG[./5;W_%6_
M+^K#OUZZ?@[_`)DVC^$M+T,WHM#=O'=HJ/'<7<DRJJKM`7>Q(X_S@"JE%2C*
M,M>;?YJW]?\`#"BN1IQTMHOZ_K\S#'PJT!=&GTM7GBAED1]\$<$$BA01MWQQ
MJ6!5F4[MQ(8\\FKN[Q;UY7?R?JMK?(%>-^1VNONUO=-W=_6Y8O\`X;Z'?ZC?
MWK!H7OHGBE$<$&X;DV%ED:,R*<=@V/;DTZ4G1=X][_CS=-]>]_RLFOZ^5OZM
M;\S2F\)VDEY)=I=74,[WJ7NY"AVNL0BP`5(VE<@YYY.".,0E9IKHV_OT9?,^
M7E\DON=_S,[_`(0A;;4Q=6MTS_:;^.[O3((X\B,.RA5C103O9<LV20.2<"G#
MW5%7^&[]6URZ^5M=.O0SJ153F;W?*ODG?U\ORMUZ^@H*`"@`H`*`"@`H`*`"
M@#-U+Q%HFBRI%JFLV%C(Z[D2YN4B+#U`8C(H`H_\)WX/_P"AKT;_`,#XO_BJ
M`#_A._!__0UZ-_X'Q?\`Q5`!_P`)WX/_`.AKT;_P/B_^*H`/^$[\'_\`0UZ-
M_P"!\7_Q5`!_PG?@_P#Z&O1O_`^+_P"*H`/^$[\'_P#0UZ-_X'Q?_%4`'_"=
M^#_^AKT;_P`#XO\`XJ@`_P"$[\'_`/0UZ-_X'Q?_`!5`!_PG?@__`*&O1O\`
MP/B_^*H`/^$[\'_]#7HW_@?%_P#%4`*/'7A%F"KXJT8D\`"_BY_\>H`WZ`.=
M\2^)&T"[TU-B&"7SIKIB"3'!%$S,P`/7=L'XU#FHMWZ)O\4DOG?\"XP<DDMV
MTE\[_HF9UQ\0<6ZM:>'M1FN&GMXU@D:*)F6;)5QE^.`>#@YP#@9(TT4^1]VO
MFES?E_5]'A[1)7\D_P#P)V_/3\KK4FU/XBZ'I6N/I,QD>XA7,^QXLPGRS)@H
M7#D;>2RJ5&>2,'&;E:,I)72OMY?U97M=Z;F_(_=[NVGJ[?UY:[:EJ7QA;Q6]
MI(=,OS)=(\T<.Q!)Y"@%I2"XPHW+P?GYQMS5U?W7,Y;1W\OZMTN3!<ZNNMK>
M=U?3TZO;SU5XX_&L%S%/+9:3J%S%;6XGGD7RE6(F/S!&=SC+;2OW<@;ADBBM
M^YC*4MHW^=M[?UT=M=!0Y9\O*[W_`">S^?;?O:Z,V'QN6>ROKZ*[T]?[/6>7
M31%'*7>614A`D!^\2&"CC.[+;<5;C:<H+5JR^>M_P6NMDOPF,E.,9[1=W?I9
M)?/KII=[)%MOB#9(3`=*U(Z@LDL;V02,R1F-%=B6W[,;74@[N<XZ\5E*2C#G
M>R3?R3Y7Y[WVZ(T4&W;S2^]-K\K>3WLM2_=^+;.UM]-DCM;NZDU&!IX(857?
MM5`Q)W,`O!`R3C)`SR*=3]W.4']E-OY-+];^B9G3?M(1FMG;\4W^G]+4LCQ%
M8G0K+6%2[DM;R-)(A!:2SOAEW#*QJQ''?I5U(.G-PENAP?/'F_K^O0BU7Q"E
MEX>74[:"1WGDCA@BGB>%B\CA%W*P#`9;)R.E2XS;4([O\.K?R5W;Y:#35G+M
M?\.GS>E_GL4+3Q/=6>B>(;S6!#*VB2R*TEM&T:3A8U?A69B#\VWJ>1^`;3<(
MNGJY75O/F<4OO7R'!7J.#?;Y:7_`I'Q;J^G-J5OJ,%K-=1+:?9Q`C1J)+ARB
MQMEFR5(!+#&0>@I\CE'E@[RYFO+1)MVOV;=K^5R%+3F?\M[??97\WI>Q6NO&
M6L64$UM<O8Q3PZ@]FVH&UD,!Q")!B(/NW,6V`;^2.,G"U#:M%Q>ZD_5J7+9>
M?7KL].JM+WFO3Y75[OR7ZH[/1[F[O-%L;F_MOLMY+`CS0?\`/-R`2OX&M:D8
MQFU%W1G3;E!-[_=^'3T+M9EA0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`%`!0`4`%`!0!S\/_)0[S_L%P?^C9:`*FD^,O[2UN?3_P#B5'RV
ME79;:EYUQ'L)&9(O+&P<>IP2!SFA?PW/R3\O2_?Y=^P?:Y?.QI_\)%:O!<M$
MDKR6T0D<^3(L1R`<+(5"L>>@Y'<"FU9_.WXV_`GF]V_E?\+_`"^>O6Q8.M6(
MBMI`\K+<R^3#M@<EVSU``^[P3N^[CG..::BV^7RO_7^7?0<FH[_UU(&\3:8L
M=R^ZY(MVVD"SF+.<X_=@+F09[IN%0FFDUU_X<JUI<O\`7W[7\M[Z;DUCK-K>
M6\4F[8TFW"D'C=G;V[X-$6I)-=?\K_D3>S:[?YV_,K3^*--A$FW[3(8YDA.V
MUE()8X!!V_,H/5ER!4\ZLFNO^3?R3MH]F/K;^M[?>KZK<G_MVQ6>WMY)&$LT
M8D!6)VC&1D`OMV@GL#@GL*N5HN2[?U]_6ROIKL3%W2??^ON\WZ#;'7(=9TR:
MZT=&F=1\B7<4MJ&)`(SO3<%((^8*1]:<HRC_`%_5GY#C*,M4RLVOW-IX<.HW
MUC&MS\VRWMYS(),9P0S*O&`6SCIZTEJXI=;?*_7^O3<>NOE_5OOT[==B6#6K
MF76KNP?3GC2)HUBE.\"7()8Y*!>`/X6;T.TG%.*NK^OX=>_X6U6KUL2TMY_U
M_771Z;7@\=_\D\\2_P#8+N?_`$4U(#H*`,/7?"UCX@D9[R6X4-:2V96-@!LD
M*ECR#S\@'T)IQ?*[K>\7_P"`N]O1]1MMKE]?Q5OPZ$5SX/LKG45O_M=U%<K>
MQWBLA3@I'Y83!4C9M)XZY8D$4E[K37G\[[_@DOD+HUY)?<[K\;[W_(CNO!EO
M='5XCJFH)9:KN-S:*8_+RRA6*DH7&0O3=CKQ1#W$DNCNO_`N;\7?Y/TL2U=U
MH_STM_7HB77?"-IKTN^6\O+7-I)9R+;2*HDB?&0<J<8(!!&/0Y!(J7%-MOK:
M_P`KM?F_7J5"7)RM+5;?U\E]VA%_PA5@(-9MEO+Q;35D99K=74*C-&(RZG;N
MSM4=21[4Y+FCROS_`!;D_P`7^FPH/DE&2Z6^=MO/;M;[]1MQX'L;J-S+?7AN
MF2V5;G,>]#;L6C8#9MSDG/RX.>E7S2O>_5O[X\K_``_-DQ26G2UOU_KT7G<'
M@?3PLS&[O3<3VT]O)<&1?,;SBI>3[N`WR+C`P`,`5%ER.G;W7;3T;?KJY._Z
M%)M34^JU_!)?<E_G<BU/P?+JFMPR_;Y;'3[>P-G$MHP61@S#S%.Y2`I5$`*X
M;@X(H?ON;GJI6TZ/>]_6_P!Q*2A&$8:<M_EM9KII9[JVNQMWF@:-J%G!9WVD
MV=W;6X`BBG@618\#`P&!QQQ3E[TN=[A%*,>6.Q'J/A^SOM'ATR$M80V[QO;M
M:!4,!1@5V@@KCC&"",<8H^TI=5_DU^3L-6LTUH_Z_/7U*!\%V+:;-8/>7S0S
MPS1S?O@/,>1MS3$`8\S=R#C`Z``<4;6MTY;;:<KNOO>K[V0[WE>6N]_.ZM9^
M5M%Y"MX.M7TZ>WDU&^>[GN8[I[\F,3>8FW80`FP8"@8VX(SD$DFC:UNE_P`;
MI_@["WTEJK6_5?<]?4JS_#^PEB1$U*_B)BFBN'4Q%KE9F#2[MR':6/79M]!@
M`8-+6Z::=-+_`.;OW'S24E-/WEL^VWRTLK::'511)#"D48PB*%4>@'2FVV[L
ME)15D/I#"@"GJVI1:-HM]JDZNT-E;O<.J?>*HI8@>^!0!E_VYK?_`$*5[_X%
M6_\`\70`?VYK?_0I7O\`X%6__P`70`?VYK?_`$*5[_X%6_\`\70`?VYK?_0I
M7O\`X%6__P`70`?VYK?_`$*5[_X%6_\`\70`?VYK?_0I7O\`X%6__P`70`?V
MYK?_`$*5[_X%6_\`\70`?VYK?_0I7O\`X%6__P`70`?VYK?_`$*5[_X%6_\`
M\70`?VYK?_0I7O\`X%6__P`70!9T?6Y-2O+RRN--GL+JU6-V25T?*ONVD%"1
M_":`->@`H`*`"@`H`*`"@"H=2LUU5-,,P^V/$TPC`/W%(!.>@Y8<4TFTVNEO
MQ_X8'H4Y?$^D07=Y:RW+++9QM++F%]NU0"VUL8<C<N0I)&1QS26JNO3]/ST]
M0V?]67J]EIKK;37;4NZ?J%MJEDEW:.S1,2OSQLC`@D$%6`*D$$$$`TVFMQ?U
M_7]:K4>+G_3S:[.D0DW9]R,?I2&3T`<I<:IIVE_$&Y;4+^VM!)ID(0SRK'NQ
M++G&3S0`\:KX45H&3Q)8*T/F#<+R++*^25/MG!^JCWRG%-6\K?UY_P";[CC:
M+O;6]_2[N_Z_5)F8MOX)^V7UQ+XCT^;[9;"UD1YK4?NP`,%E4,_`Z.6'IBJO
M>]^KO^-_ZZ^>Y'+HE?967]?TK]-C5M]8\*VJ6R1^([#9;,QB4WD6%!!`7KT`
M.!]!25]V[NUOQ3_3_/74.5)66B_X%OU_RT,2UL/!>GW%]<6'BFQM)[I]ZRP/
M9*\)W$\-Y>6ZD?O"_P"?-3&/)%0CLO\`*WY,MVE+F:_K1^NZOV\K:%^&Y\+P
M7=M.OC"#9`J@PF\@V2,N<,QQNS\QZ$#VHC%1M;IM]W+\].XGJO-_YW_,7[7X
M9\J6+_A,X?*:17B3[;!B`*V=J\<@]/FW''0BCE7*H_U:UK?<_7NV._O7_J][
MW^_7MY6'->>%6GA<>*[58415:W%[#LD*C"LW\61@="!QR#3DN9R;ZW^5U9_A
MIK=?,F*Y5%+I;\-5^/:WW%RWUOPM:QR)'XCT_P"=%0DWD60%7`QSUHG[_-?J
MV_O27Z!!<EK=$E]Q5U*Y\"ZQI*:9J&I:+=6\:;8Q-/"YC.W:&7=G#8[U4GS2
MYWN./NI)#=9NO!^MZ?)97'B+3DA>-8U"W%NP0!@>%<,IS@=01P,8I?:YNM[_
M`-?U?ST0X/D5E_7]?\#9LK^,?$?A]_A]K]I;:Y82R-ID\<:+=HS.?*8`#G))
MIMW=R8KE22.WI#"@`H`*`"@`H`*`"@`H`HV^JPW&L7FF+%*LUK''(SLN%8.6
M`V]S]PYXQ]><4HWAS^;7W6_S&TU;S_K]3-N/%MI;7E[;R6=WBV1V64*A2=EV
M[D3YL[@74?,`"<X/!K-235T^MEYZ\OYZ?<#LM]EN^VE_5Z:Z)]M]#3TK4DU6
MQ%RL$MNP=HWAF`WQLK%2#M)'4=02/>JTLFG?^OTV?F+5.S5OZ_RU_/4F2YW7
M\UKLQY<22;L]=Q88_P#'/UH`GH`*`"@`H`Y_QW_R3SQ+_P!@NY_]%-0!8URX
MO[>?3FL9/E$S-/#L#&:,1ME1W!S@C'=<=#2YE%MRVL_S6NGY=?6P/96WO^C?
MXV^10TOQ-+?.CPI#<V#3M&;E9L-\TC"/:@7#+@#)W#Z'FJ2UL^WX\O,_E;;?
MTMJ*;Y79?/RUM]]]T[6]="_>:I=0ZD;:.U!@C\O,HF`=F=L!0I4C&`<G([8]
M0EM?K=Z>D;_Y6_I--V=O3\78QU\7W36%G<RV!@N)+EK=K?;,`#L)4NTD2LB]
M"6VX]":J*3DE?=?C=?ILG:[:\@D^5OFT2?KI9_+?LVM-]S6UO6[C2?FBL5N$
M2!YI#YC9&,`!55&+$L1T'3)Y.`8;23^27JW;^MREND_-_=:_;OI^:*(\2ZA<
MZ%'<V^EB*\;?OCN6E@5%49+*9(@S=1@%%!YY`&:BM+D@Y+LWTZ?UUMIO8=*T
MI6EW2]>OY=KZZ>9H0:V-BB6,D@-N(/)VHK$@8_VJTJ24&_23^Z5B*=Y)+T7W
MJYGW.O:LD,#-8VL0=F,GE7F\B/864C]W][U!&/0FB*?.HOY^MXKYK7R?ZJ4_
M<<E\O2S?R>GFOTG/B*[%M>S#3HCLA::T47/,H4XP_P`O[LYQTW=_3%*'O)=W
M;_R;;_@Z>C8Y2Y6^R3_\EW_X&OK8U-*N[F\LRUY;Q6]RCM')'%*94!![,54G
MC'856C2:_KH_Q0^K7];7,S3O^1YU[_KUM/YS4AG04`%`!0`4`!.!D\"C8#(L
MO%?AS4;Q+.QU_3+JZ?.V&&[C=S@9.%!ST!II-JZ!^Z[,UZ0&-=:3?S>*+358
MKZWCMK>VD@,#6S,[;RI)W[P!RB\;?7U&*C)J,EWM^%_\V4Y>ZH^=_P"OO,N;
MP?>W,UV\VKQ[9%=H0EICRY7V%F.7.Y<IPO'!()/!K%4H)*VZ=U_X'SV?SMVT
M1.K34NN__@/+IVT[WUZVT-W1M/ETVP,5Q<+<7#RO-+(D?EJ69BQPN3@#.`,G
MIU-:)1BE&*T_IO[W<+MMM_U;1?@OO[;'$^.OAW:^++R)+-H[._M8UF@D8$ID
MO\P90>00N*`,S3=6\2_#O7;31-?:TN=`O+B3[+=1C;Y"'<PC"_>.,=P<`@;O
M0`[67Q?X7F(,MVDA'3=;N<?^.T`/LM<\,:A>QV=K);/<2YV(8"I;`)(&0,\`
MG\*`-G[!9_\`/I#_`-^Q0`?8+/\`Y](?^_8H`/L%G_SZ0_\`?L4`'V"S_P"?
M2'_OV*`#[!9_\^D/_?L4`'V"S_Y](?\`OV*`#[!9_P#/I#_W[%`!]@L_^?2'
M_OV*`#[!9_\`/I#_`-^Q0`"QM`01:P@C_IF*`+%`!0`4`%`!0`4`%`&1>^);
M'3[Q[6:#4VD3&3!I=S,G([.D94_@:(^\[(;5C7H$8XT%DUR]U5-6O4DNX4A\
MH"'9&%)*E<IG(+-U)^\?08I2M'E\[_UZVM_P0DW))=K_`(E6X\'VES=7LTE]
M>[;E7"QAU"P,VW<Z?+G)**?F)`YP.362IQ4;);.Z\O>YO_2M?NZ`]=]GNN^E
MO5:::-=]]35TO34TJQ%LL\MPQ=I'FF(WR,S%B3M`'4]``/:KTLDE;^OUW?F&
MM[M_U_PVGYZG&ZYX,NKKQ:^J>&M7;1-2M[*.(LD"2I-&SR$J5;@'*CYL''/!
MH`YW2/BEK/ASQ''X=^(%O%:,%8B^VX608RK9`"L.JG:!SVZT`>H:1KVEZ[$\
MFEWB7*1XW;<C&1D'![$=Z`-&@`H`RO%&GSZMX2UG3;7;]HN[*:"/<<#<R%1D
M^F30!2;4]?9E9O"JEDY4F]CR/IQ0!57[?'=Q72>!K5;F$,(Y1<0AT#'+`'&1
MDDD^N:%IMVM\ELO1"LG]]_F^OJ3O?:W(6,GA&-]V,[KR,YQT[=J5EM_7;\AE
M:UCO;"S^QV?@2TM[7+'R8IX43D8/R@8Y'6G+WE9[;?(22B[KU^?<L2W>LS1-
M%+X/BDC:,Q,K7<1!0]5(QT/I0];WZCB^5IQTMMY%(6<RZ?%IX^'U@+**3S8[
M<2P>6C_W@NW`/)YH>NXTW&]NI8B;48+^2^B\$6T=Y(H5YUN8A(P`P`6QD@#B
MCOYB>J2[;>1''#=PPK#%X#LTB64S!%GA`$A!!?&W[Q!//7FA:6MTV\O0._GO
MY^O<DB?4H)+F2'P3;1O=-NN&2YB!F/JQQ\Q^M"]U66V_S[B:3=WZ?(LKJ>OQ
MYV>%0N3DXO8QD^O2C;08[0[?4FUW5=3U"Q6S%S%!''&)A(?DWY)(_P!\4`=!
M0`4`%`!0`4`<;)J6J?\`"Q(+'[7?166Y@8GM46VD419PLC("SECG"L>$;(`%
M525U)O73[M>GE:W=:[[(J:M%/\OU_%=]8^9V522%`!0`4`4!_P`C`_\`U[+_
M`.A&@#F?&]IJO]O^&-6T[2#J4>G33O,D942#=$0NW<1U/]*`-3P;XLA\7Z1-
M>QVDMG+;W#VTUO*P+QNN,@X^M`&IJ>CZ=K,"0ZE90W4<;[T65`P5L$9'O@D?
MC0!F?\(-X6_Z`-E_WZ%`%.+0=4\.:I/)X9MK&33;I=TEE<7+6ZQ2@`;D*Q/P
M0.0>_-`%S[9XP_Z`6C?^#>7_`.1J`#[9XP_Z`6C?^#>7_P"1J`(KG4O%]K:3
M7'_"/:3+Y2%]D>K2EFP,X`^S<F@!T7C?1GA1W^VQNR@E#I]P=I]/N4`/_P"$
MTT3^_>_^"ZX_^(H`/^$TT3^_>_\`@NN/_B*`#_A--$_OWO\`X+KC_P"(H`/^
M$TT3^_>_^"ZX_P#B*`#_`(331/[][_X+KC_XB@#9LKRWU&Q@O;242VUQ&)(W
M`(W*1D'F@">@`H`*`"@`H`X+XDWDD`TZW2XN(6N"Z1F#4?LK!R5&<*X>3`)(
M55<D@#'-515ZT?Z5M;Z?=OIOJE<T2M!R[?+\>FS7SO9V.\7A1SGBI,HZ(6@8
M4`%`%"'_`)&"\_Z]H?\`T*6@"'7/#6B^)+9H-7TRVNQL9%>6)6>,,,$HQ&5/
MN*`.+G^"GA^38\>IZS'/%"D,,HN\M&J8VXXXP!CTH`I:O\/?$F@V;:OX;\8Z
MU<ZC:1$);W+"X690,;`K$#/N<_G0!TOA/QY_PD-W<6-_H=_HMY;P+,Z7R;`P
M)()4^@XZXZ^U`'8T`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'"6,>F
MV_Q-EB^V74FJ^2!(QCL6\U=@^^8U\]1T.6VKD``\J#=/6$VMOZ^7WZVZ=5=5
M-V;^7EJ]%?\`2_YG=U!!DS:_!!KT6E&VN&+X4W"A?*1RK,$/.[)"$],=.>12
MBU)M7V_.R=ON=_0'I_6RO9/YO32[[I+4I7GC.QL9]0CFM+H)902S>;^["3"+
M;Y@4EN"-P^\%'H<40:G'F7>WXM?FF.2<=>BW\M+V[W:U5K_>:VDZE%K&E6^H
M0+MBG7<H\R.3C/\`>C9E/X$U<H\KL1&2DKK^K$44L<GB"3RY%?;;`':<X.XU
M)1I4`>8?$?3+7PYJ.C^,[5I+1;;48OMZPR%$EC8D%BH^4MDC)/4?2@#T73=2
MLM8T^&_TZY2YM)@3'+&<JV#C^8-`%J@`H`*`"@`H`*`"@`H`*`"@`H`Y3PE_
M:.D2IX7O_LTBZ?80M#/!N!=<LGS`]_DSQZT`=70`4`%`!0`4`<AXMEUBTOK'
M^SKS4MD\A#QVD:,5'RC`S;2*.Y^=T&2?FQ]VJ5G42>W];[?@[]DWO;2<+[6_
MJ_5_<O\`@]>.E29K8R;;7X+G79M+6VN$*;ML[!?*D*[=ZK@YR-XZ@=\9P:46
MI*Z?])V?W/1_(;T_K9VNE\UKI==W?0I7GC.QL9]0CFM+H)902S>;^["3"+;Y
M@4EN"-P^\%'H<40:G'F7>WXM?FF.2<=>BW\M+V[W:U5K_>:VDZE%K&E6^H0+
MMBG7<H\R.3C/]Z-F4_@35RCRNQ$9*2NOZL16TL<NO7ICD5P+:$$J<X.Z6I*-
M*@`H`*`..\:_#3P_XX5YM0@9-1$/DPW:NV8ADD?+G:>2>H[T`<+HGB'Q;\-]
M&U+2;W0'URPTBYPUY#=+'Y,3A2BB/;N(^;/'`R1T%`'I^@^+M'\2W5[;:7--
M))9;?.\RW>/&[./O`9Z&@#<H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#A(
MKV6T^)DEG!JMNT-W,6FL8K^)Y%80?>>'R-ZCY%_Y:XR0>^*NE[T6GT3MY>]\
MN[[_`*A-K39/3R;_`,W;\%V1W=0!CS^'8)]=75?METC+AO(5E\HN%95<@KG(
M#'C..F0<5,8J-[=?P=DKKY*WW]QMW_K=)W2^_72S[NVA5A\'VD&LWFL)>3C4
M[F#R/M0A@61!A02"(QN)VJ?GW`8P`!Q5W:BXK1-W_/\`S]1=KZV_X;^NGD:N
MDZ7%I&GK:0R22_.\CR2D;I'9BS,<`#)))P`!Z`4-WMY:`VV[LBBACBU^3RXU
M3-L"=HQGYC2`TJ`(KFV@O+=[>ZACG@<8:.10RL/<&@#SNVTWQEX)T1H=/32Y
MM&L9PT5G9VTTMRUN78NJY;E^1CGUYH`Z/PYXVL?$=W=6:V&H:;=6RQL\.HP"
M%_GW8`&3D_+G\10!T<<L<J[HI%=0<94YH`?0`4`%`!0`4`%`!0`4`%`%9;&W
M74GU`(?M+Q+"S9/W%)(&/JQH`LT`%`!0`4`%`'"_$&_FTNXL+VUU>"QN$BE5
M8WU"*"2<$H2J(\$OF'*CI@@G'.:JEK44>C:_/Y=^Y3:4+.R\WI^/Y_([D?=%
M20MC%C\-10ZM<ZA%J%XCRA]D>4*0,^W<R`KG)V#[Q8#G`&:4(J"LE_3=VO1M
MZ_+L.6OE_G:R?R7;3NFR-?"5G'KU_K<,\L.HW</DB>.&%6B!QD@^7ES\J_ZS
M?C'&!D4TW&+BGN[_`)_YC;OO_7]?<:.DZ7%I&GK:1222_.\CR2D;I'9BS,<`
M#)))P`!Z`4V[V\M!-MN[([6*.'7KQ8HU1?LT)PHQ_%+2`TJ`"@`H`*`,36/!
M_A[7O/?4M&L9[B:,QFX>W1I5&,##D9!';TH`XK5/AM`?%#:E<:7/XA1[181)
M<7PADC/S*P^0*""K`<Y/%`&5H5UK%MI,>E:9XVTS2G6?R+73I[-6D@`9E$18
ML2Q)V@$Y)_&@#<T[XAZAH46DZ/XOT35AJT\L=M+?);(+1I)&^4"0-@D`C.!V
M-`'HL<T4O^KE1_\`=8&@"2@`H`*`"@`H`*`"@`H`*`"@`H`*`.9LCXFDU:WE
MN5>*TCD,,L3>41(NUCYP*_-][8JC@XW;EZ$%)>[>IO;\=/+=^]Y6ML[H<K)M
M+;I]_7R2[:W[HZ:@04`%`!0!0'_(P/\`]>R_^A&@"_0`4`%`&+K7A+0?$5U:
M7.KZ9%=S6AS"TF?EY!['GH.M`''^'-$L?`WQ0U&PL;-K'2=6LHI("9!Y1F1B
MI1<\[B&SC/K[8`/2J`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`YK7-(US4+
MFX2SOA;VQC\R)TN9$<3!<(I"C&P'YCSS@`J1135I\T]5?;RTOU\GIL[WT:U;
MMH_O6U]^O2]UJM5;KL=(,X&>M!*O;46@84`%`%"'_D8+S_KVA_\`0I:`+]`!
M0`4`%`!0`4`4M6TN#6=.:RN6D2,O'(&B?:RLCAU(/J&4&@#&N_!5M?6SV]WJ
M^K3PN,,DER&!_`B@#@/$7PRNO!=J^N>`I)HYX866XMR[L\R9!`0(!SD<Y]!Z
M4`=AX?L[/Q#IINK3Q%K+-$YAG3[21Y<JXWIRHS@G&:`++6=QH?B?1$35-0N;
M>]>6&1+B8.NX1EUXQQ]QN:`.LH`*`"@`H`*`"@`H`*`"@`H`Y!)KO_A8,T2W
MP^R@QET:6;KY;X14V^7ZL6#9X`(Z&BEM*_\`6VNO3III=/KS(<M%_6FJ_KH_
M>[)7Z^@1ASZ_-#XCBTY;)6M"RQ/<>=AED968`)MY7"\G=U8<'DU,)QDVK]6O
MFDI?D_P!Z+3R;]&[*WG?>]M.KV,JX\=I!KNI:4MK;R36D3O&BW8\TLI0`2)M
M_=JQD&ULMD`G%$)<T.?;5+[Y./YJ_H[CDE'5[+?OM?1==/-:Z>9T.C:A+J5@
M9;BW6WN(Y7AEC23S%#*Q4X;`R#C(.!UZ"J3C)*47I_2?W.XK--I_UU7X/[^^
MY%;74-SK\ODONV6X!X(P=Q]:`-6@`H`*`"@#F/&7A)_%$.GRVE^FFZGIUP)[
M:\-JDY0XP1M;L>#UZJ/2@"A)X9\<MY^SXA[-Z*L?_$GA/EL,;FZ\YP>.V?:@
M#/L_$WB#PUKNL:?KMIKVO0Q1QO:W-GI"B-L(-X!0\L6/0],4`6+OXJV=@UK]
MK\,>([:.X:-1+/8>7&C.P&UF+<$>E`'?4`%`!0`4`%`!0`4`%`!0`4`%`!0!
MQ7CV*.2;3F:;R3&L[-*;=9?+C\L[R-SKM;'`/S=>1C-%._M4U_79?/5[=%JF
MDG<;NR6KNM/FOULM]F_EVBXVC'3%-F<=E8Q+37YKCQ%+IS62I:YD6*X$V6=H
M]FX%-HVCY^#DYVGIQF(3C-:/77[D^5_C^8WI^"?JU=6\K;WL[]&M3*N/':0:
M[J6E+:V\DUI$[QHMV/-+*4`$B;?W:L9!M;+9`)Q1"7-#GVU2^^3C^:OZ.XY)
M1U>RW[[7T773S6NGF=#HVH2ZE8&6XMUM[B.5X98TD\Q0RL5.&P,CC(.!UZ"J
M3C)*47I_2?W.XK--I_UU7X/[^^Y%8W5O=ZY>O;3QS(+>%2T;A@#NEXXH`U:`
M"@`H`*`"@`H`*`"@`H`XZ\^'EO<ZAJ%U;>(M>TU;T[GM[&[6&)&)!+*H7AB1
MR>IR?6@#/U+X8"XB:X'BWQ3)=01?Z/\`\3'&QPFW<,+PQ&03WW'UH`P?AUXS
MM['6-2T?7=8U,W;3VMI;Q:CN=O-,>UE!`.,NK<GT%`'K]`!0`4`%`!0`4`%`
M!0`4`<;IVBQ7/CBXUVWU.*XB<)-]GDAGW1@QF,%29?+!.UCGR\\L,\TZ4DZ?
M,MFM'ZVE^3\OS"<DY<BT:W^]K]+?),[*D!FRZ!IL^L+JKP/]L5=H83.%Z$`[
M`=I8!F`;&0#UI)<MTNN_X?Y+[@[?U\GW5];/2^NY"_AC2I3<F:*><W$/D.9K
MJ63:G&0NYCLS@$E<$D`GD9IO73S3^:=U]SV[`M%;IYZ^6M]].Y>T_3[;2K)+
M2T1EB4EOG=G8DDDDLQ)8DDDDDFFVWN+^OZ_K1:$0_P"1@?\`Z]E_]"-(9?H`
M*`"@`H`*`"@`H`K:AI]MJFGSV-Y'YEO.A1UR0<'T(Y!]QR*`/,!:W/PDU/6+
MO3-$U+5=`N8(YB5N`1:%`X8`,Q9LDY)XP#WQ0!ZI!+Y]O%*49-ZAMK=5R.AH
M`DH`*`"@`H`*`"@`H`*`"@`H`\_\9ZIH[^(]/M;S6-&L[BU8XBU:W29,LH=9
M0#*A4C85#>K8I4&IU'9:IV\^CLGY\RZ=/(<VHP46M_NVEO\`=^7<]`'2F2MC
M*7PYIB:C<WZ0RI<W*E7=;B08SC)4!L(3M7)7!.!FB/N+E6U[_C?\VW;9A)<W
M]?*_JEHGNELPN/#FEW4]Y-<PRS/=QF*3S+B1@JG&0@+8CS@$[,9(!Z@4K:6\
MT_FM5]W0J_1[?AVVV9;T_3[;2K)+2T1EB4EOG=G8DDDDLQ)8DDDDDFJ;;W)_
MK^OZT6A%#_R,%Y_U[0_^A2TAE^@`H`*`"@`H`*`"@`H`*`"@`H`X_P`1>$K^
MXM[`Z#>I;SV^L+J4@N22D@.[<OR\X^;I^O>@!/".N>)[OQ!K6C>)K.P26Q6&
M2*XL!((Y%<-Q\_)(VT`=C0`4`%`!0`4`%`!0`4`<3I3>&CXRE73O"R0W<,KQ
MM>+H[1,DFTEF,Q0+M(('!R2W0@YHI)J+Y=(V5NFS::_*R\G?5"E)-M/=/U[-
M?F][>6ZOVU`PH`*`"@"@/^1@?_KV7_T(T`7Z`"@`H`*`"@`H`*`"@"IJFF6F
MLZ7<Z;?Q>;:7,9CE3<1E3[CD4`<I'\*/"D7D;(+T>0C1I_I\W`;.?XO]HT`$
M?PH\*Q>1M@O1Y*,B?Z?-P&SG^+_:-`'/,FB?"[QREQ<+>67A[^R?*6[EDFGC
M\]IRWE@8;YMH)^E`'0R_%WP)#Y^_7T'D%0^()3@GIC"\_A0!O:%XJT7Q,;H:
M/?+=?9&"3;490I(R.H&?PH`V*`"@`H`*`"@`H`Y'Q;XP?PW?VENUFRQ2J76X
MENK>&*1AQY1,KJ1U!)`)QT!YP07/44;VUV[IW7KH[/3TTNKC=NFGY6:^6JON
MU^=NM!R`:!)W0M`PH`*`*$/_`",%Y_U[0_\`H4M`%^@`H`*`"@`H`*`"@`H`
M*`"@`H`*`.+U7P+>W'B+4M;T?Q+=:3=7\44<H2!)!^[Z'YO:@!LGA#Q4_G[/
MB#>IO"A/]!A^0C&3TYS^'6@`E\(>*W\[9\0KU-X4)_H,)V8Z]N<_A0`2^$/%
M3_:-GQ!OD\S;L_T&`[,=>W.?P_&@#*\6:1XOT/PSK&K6OC:^N)+>(2QP_8X1
M]WJ,A>X]!^=`'H=C))-I]M+,I65XE9U/4$@9%`%B@`H`*`./CLK3_A84UV9-
M-DN591^\TIS<IF(@*ESNQC"L2`O&2.,BG2TC*W^77KW[?+R8YZV_X?K^&Z_/
MJ=A2$<Y<ZY>Q>+(K%#:_8?,2!XV4^<7:-W#!MV,#8!C;SR<C&*FG)2;5GNU]
MR4KORUMZV[@_+HD_DWR_+O?6^UEN9<GBG7)?$NLZ586<4@@MI6LB\!`EE01_
M*',@#\O@C"8/&X\D5#WH.7FONNT_R\O35-N:<;6[?*]KI-]+^CNKNZV.B\.:
ME+JNB17-Q_Q\AGCF'E>5M=&*L-H=P,$$<,P]ZJ22M;JDR4I*ZEO_`%;J^G]+
M8+>X6?7Y=J2)MMP/G0KGYCTSUJ1FK0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!Y
MA9>,-"\+^/?&@US5Y+4/<6QC2X1BN/)'W,9R./0=!0!O2?%7P/%YV_Q#`/)8
M*_R.<$YQ_#ST/2@`D^*O@>+SM_B&`>2P5_D<X)SC^'GH>E`!)\5?`\7G;_$,
M`\E@K_(YP3G'\//0]*`.LMKB*[M8KFW<20S('1QT92,@_E0!+0`4`<OXKG2U
MN[*;^T=2L76*8M)9+;D!``QW^:K?W0!M]>>.:=/X[>GH][+37O\`\/:])<RY
M4M;_`#[?JCIP<J#2(3NKG.V.N7MQXIFLI#:FR)F2)$4B5&B\O)8[B"#O/``Q
MQUSQ-.2G&]GU]-).-O5VNOGV&^MNC2?S7-\NUM;[W6QER>*=<E\2ZSI5A9Q2
M""VE:R+P$"65!'\H<R`/R^",)@\;CR14/>@Y>:^Z[3_+R]-4VYIQM;M\KVND
MWTOZ.ZN[K8Z+PYJ4NJZ)%<W'_'R&>.8>5Y6UT8JPVAW`P01PS#WJI)*UNJ3)
M2DKJ6_\`5NKZ?TM@L;A;G7+UU21`+>$8D0H?O2]C4C-6@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@#E?B5'YGPV\0)Y+S?Z(WR(<$_3@].OX4`;VDKY>C
M6*>68]L"#83DK\HXS0!<H`*`"@#AK?3#+\1QKHN]UI(BK'$]PS+N,9P5A$:A
M&P'^<NQQD8&X8=&RA)]_^`_DM4[6WUOO>IM;+IO]]OGMY;+LCN:1)4DTO3Y=
M06_DL+9[U8S$MPT2F0(>J[L9QR>*5MUWW!ZVOTV\BNOAS0U:X9=&L`US$(9B
M+9,RQ@`!&XY7``P>.*IN]T_7YB44K66VA>MK6WLK6.VM((X+>)=J11(%5!Z`
M#@"ANX));%4?\C`__7LO_H1I#+]`!0`4`%`!0`4`%`!0`4`%`!0`4`%`#'AB
MD!$D:N#C.Y0<XZ4`-:W@??NAC._&[*CYL=,^M``UO`^_=#&=^-V5'S8Z9]:`
M,+QQ;12>`_$8^RB5GL)B54`,Y$9QSCK0!;\*IY?A#1$\IH=MC"/+8Y*?NQP3
MWQ0!KT`%`'G/Q"N/#EYJFGP:KJ]C97&FR?:$2X;,F=H8-&OFJN>"`75QGC&,
MY*#3K<T5=K3[[:?.Z\]-&K(M_#R-;V].N_7\?ST]%4Y4'VH,XNZN4FT;2VN;
MFY;3;0W%TH2>4P+NE4=`QQEAQT-"TV]?GW"24OBUTM\GNO0:^@Z/)/=SR:39
M/->)Y=S(UNA:9<8VN<?,,`<'THZ6Z#ZWZENVM;>RM8[:T@C@MXEVI%$@54'H
M`.`*;=Q));%6'_D8+S_KVA_]"EI#)[^]BTW3KJ^G#>3;1-*^T9.U02<?E0!B
MQ^)=2EC61/!NLE6`(/FV?(/_`&WH`=_PD.J?]"9K/_?VS_\`C]`!_P`)#JG_
M`$)FL_\`?VS_`/C]`!_PD.J?]"9K/_?VS_\`C]`!_P`)#JG_`$)FL_\`?VS_
M`/C]`!_PD.J?]"9K/_?VS_\`C]`!_P`)#JG_`$)FL_\`?VS_`/C]`!_PD.J?
M]"9K/_?VS_\`C]`!_P`)#JG_`$)FL_\`?VS_`/C]`%G2==.IWMW93:9>:?=6
MJ1R/'<F(DJY8*08W8=4;OGB@#7H`*`"@`H`*`.5^)4?F?#;Q`GDO-_HC?(AP
M3].#TZ_A0!O:2OEZ-8IY9CVP(-A.2ORCC-`%R@`H`#P.F:3T`XS09?"%SKS2
M6'A=K+58Y65IVT1XBK[<MF8)M!()'+<^^1FJ:M#W-%;TTO;;3MMT^3M+E>33
MW3]?/]?UVU.SI%!0`4`%`%`?\C`__7LO_H1H`OT`%`&7J7B70=&N%M]4UO3[
M&=EWB.YNDC8KTSAB..#^5`%/_A._!_\`T->C?^!\7_Q5`!_PG?@__H:]&_\`
M`^+_`.*H`/\`A._!_P#T->C?^!\7_P`50`?\)WX/_P"AKT;_`,#XO_BJ`#_A
M._!__0UZ-_X'Q?\`Q5`!_P`)WX/_`.AKT;_P/B_^*H`/^$[\'_\`0UZ-_P"!
M\7_Q5`!_PG?@_P#Z&O1O_`^+_P"*H`/^$[\'_P#0UZ-_X'Q?_%4`:>FZSI>L
MQ/+I6I6E]'&VUFMIUE"GT)4G!H`NT`%`!0!@>.$\SP#XA3RFESI\XV*<%OW9
MZ4`6/"J>7X0T1/*:';8PCRV.2G[L<$]\4`:]`!0!@WNNZI9ZP;./PO?WMOL+
MK<VTL&T]."'=<'D\>W&><.'O:/3;_A^_X?I=2=FDNM_T_K?];;U(84`%`!0!
M0A_Y&"\_Z]H?_0I:`*WBS_D3=<_Z\)__`$6U`%ZS+#2X"BAG$*[03@$[?7M0
M!RD.J_$0_9_-\,Z4N9B)<:B>$XP1\O7D^O3I0`ZVU3X@O):BY\-:6B-/B<KJ
M!)6/CD#;UY;UZ=*`*'B_3/$EYKUU<Z3<7=M#;6T+J\5S,`YW2;XUA`V.6&W+
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MU?96N]SN*8!0!S]A_P`C]K?_`%X6?_H=Q0!T%`!0`4`%`!0!GZWH]KX@T2\T
MF^W_`&:ZC,<FQL,`?0T`6[:WCM+6*WB&(XD"*"<X`&!0!+0`4`%`'/GPWN\6
MKK:SVPV==MMBX;Y-NPS;N8^=VS;]X`YHI^YS>?\`P-^[TMZ:=!MZ6_I>G;_@
MON=!0(Y&]URXA\=P6`U,1I\@^PE4_>1F.1FFR1NX95&0=HQ@C)%13DVY76B;
M^2LFG\V[?\,QR6R]+>;O9KSLM;*S6[T,"?QCJ#>)=?AM]34V%O:-)$R-#((@
M/*_>;0NY1AV8%RP?!(``YI75-M_S17:R<FGZ62OKZWW24FKIPUT;MW=KK1:N
M_=-6VM=IG9^%KZ34-$6=[W[<HFE2*ZPH\]%<A7^4!3D`<@`'J.M5K9-JS_K7
MYK7RN+1-J+NOEVUV[.Z^6NI+;R32:_+YL'E8MP!\P.1N//%(9JT`%`'/V'_(
M_:W_`->%G_Z'<4`7=>UG^P=*>^_LV_U':P7R+"#S93D]0N1P*`.<?XCA/._X
MHSQ6WE1I)\NF??W;?E7YN2-W([8/I0!H:5XP.L7T]FOA_7+`QV_G"XOK+RHC
MP#M#9/S#=T]CZ5%1N,&T5!7DDSF;'Q-XCTKPU::MJ337(F1IUCO&MXFD`M]V
M"\8V(F\9!/('WJVJ>Y.46MMO_`HI7Z7U>VEK=;G+&<I*$N^_G[LGIUMHO.]S
M9TWQV;^UTB9K*U@:_BDD:-KX,Q*$@I#A2)FXSP0,$')K*K+V;EHW:*EYNZ;L
MEY6U]4;TWSQOM[S7EH[;^?1>O8QA\2KZ?0+76Q9:=9HMS)'-#)JT3QLHBW#]
MZBMM;)`"D`YP.]:-<K5];INRU?Q)>[_,][:_D*5W)16GO6^5GO\`RZ^O;J=/
MIOBMM0\32Z2+6!%C0DC[3FXCP%.9(MOR*=W#;CG'3GB(OFOY7]-';?N]TNJN
M^@VTE'SM^5].Z6S??0Z6F,*`.?TC_D;_`!'_`-N__HLT`=!0`4`%`&+XOLY=
M0\&:W96]NUQ-/931I$K;2[%"``3T.:`)_#EL]EX7TFUE@,$D%G%&T3-N*$(`
M5)[XQC-`&G0`4`<IXRL-/U&;3K:\U33K*>5V2W%[$'=F.!N@RZ[91QAAG&>E
M%-?O5)*[6OGIK]VFOR[%)N*YK:+OM\_Z[G5@8&*"$K*QQUGX@D_X3*_MKC5D
M\B$2^=:.$46J+Y>QRV`PW;F/S$@]L8-31;G'5=_OYFDK>:U_X=#G:+UTM^*M
M=O7>STNK);/74QKSQ;JD7BKQ%:)?[+6TM79!F)S`1Y0\PH%WIC>Q!<L&P2``
M.2+_`'7,_P":*]$Y-/[DKZ^M]TG/1KE5W9Z=W:ZTW=]KIJVUKM,[#PM?27^A
MK.][]N432I%=84>>BN0K_*`IR`.0`#U'6KULFU9_UK\UKY7)T3:B[KY=M=NS
MNOEKJ2V,SS:Y>M);26Y%O"-LA4D_-+S\I(I#&>+/^1-US_KPG_\`1;4`:%A_
MR#K;_KDO\A0!8H`*`,N?Q#IMMK<6CRRRB\E"E0+>0ISNP#(%V`G8V`2#Q0M=
MOZZ_/3703:7]>=OS-2@9'#,L\>]`X&2,.A0\''0@'M^-`D[C8KJ&:>>"-\R0
M,%D&"-I(!'Z$4E)2O;H[?D_U&]/Z_KL%O=P733K"^XP2&*3@C#``XY]B*?1/
MO_G;\T)23;2Z?Y)_DT%I=P7MN)[=]\1+*#@CD$@]?<&CHGWL_OU!24KVZ-K[
MG9_B8MA_R/VM_P#7A9_^AW%`SH*`"@`H`*`"@`H`*`"@`H`*-@/+;.^T77OB
M3.`DL=X\GEAXM0M8"\:QAE<&%A<2`X!VL2F#DX*@#2DFH/[_`)IVU6WS:\EH
M]55;;=.:VT_7K:V[^'K;K>WJ59C"@`H`*`*`_P"1@?\`Z]E_]"-`%^@`H`Y^
MP_Y'[6_^O"S_`/0[B@#H*`"@!"0H))P!U)H;MJPW*FFZOINL0-/I>H6M]"K;
M&DMIED4-UP2I//(IM-*["_0L2SPP*K32I&&8(I=@,L3@`>Y-+=V$VDKLDH&0
M_:[86GVK[1%]FQN\W>-F/7/3%"UM;KM\]OO$VHW;Z?IO]P^::*WB:6:1(HT&
M6=V``'N31Y`VDKOH/H&<_I'_`"-_B/\`[=__`$6:`.@H`*`"@`H`*`"@`H`\
M_P#''B71[75H-,U*T>Y41.P!U:*U@=_E_=RJTJ[QAE)#*W#<*V354H\T[>B[
M[WZ>7WW[:7<FX636CN_/333;SZKYZV[FSM+:QM(K6SMXK:WC&$BA0*B#T`'`
MI-MO4B*26A/2*"@`H`H0_P#(P7G_`%[0_P#H4M`$'BE&D\(:TB*6=K&8!0,D
MG8>*`,ZS\;>&$L;=&URS#+&H(,@X.*`,<GX7LQ)_L;)Y_AH``?A<#D?V-_X[
M0!5U.?PMJ7BN/6O^$ETF,+$D9_<@W"A=_"3;OE5M^&&TY`QWH6D91[W_`!26
MO=+=>>I,E=IWVM^#O^.S\BM"WAY8;077BO1+N6WFCDQ-:;HB$0(,(9.'`4$/
MG@YXYI6_>NKW;?W\NW_@.GDVO,(Q4*?LH[))+T5]^^_EJDR2)?!Z7B7;>*+`
MW,;LT<P4"2,-YFX*V<C/F#/^X/PB<'*GR)VTL[=?<4?P:YEY_>*G'DDY/6^M
MNWON7ZV_JQG+IOA,:3]B/B+PX=TWF.@T\"`GR]FX1>9Q)@9#Y/.>.:;A>3DF
MUOL[6OR_#V:MH^EV:*32\]/G:_Q=]]=MD7KI/"ESJ45TWBG3)`D_FYN(A))'
MC9@QON&Q_DY;!SZ<5:TES7MZ:?:E*WH^:TEU2Z&2ARQE%/?_`.14?OTNGTN]
M&=)I7BGPMIFGK:_\)%92;7=MV\#[SENF??%/HEV27W)(<(\M_-M_>V_U'Z!J
M5GJWC+6[O3[E+FV^QVD?F1G*[@TY(SZ@$?F*19U5`!0`4`%`!0`4`%`!0`4`
M!Z<<4GMH!P6EW>NV_C2'3K[5YYX!D.KR*4+^7NV`K9HI8=<"4'`R1U%73LU+
MR_S6O3]==/2JBUO';]//>WS^\[VI)"@`H`*`*`_Y&!_^O9?_`$(T`7Z`"@#G
M[#_D?M;_`.O"S_\`0[B@#8O;>6ZM'AAO)K.1L8G@"%TY[!U9?;D'K0!C_P#"
M/:I_T.>L_P#?JS_^,4`6+31KZU>1IO$6H7ZLA417*6ZID]_W<2G]:F<>:+2*
MB[23.3TCPCXETC2$AMI;:&?B-T_M*>0$>28_,\QDW9!VD1XVC;P1FKK^_&2C
MHVI?)NUO5Z;O6S[)(PI4W"47)Z1MI;>W-?T3NG;577G<W(-%UI-0GE>ZRK3P
MR"7[?,=T:D;D\HC8G`(R#\W?%$-'=]Y?CS6^ZZ^Z^XZD92@DGKI^#5_6]GJ^
M]MBG/X:UU8+HQ7[SO<,C21/J5Q$&Q(QPKJ"8OD*CY`,E<'UK-1DW%-^ZK>M^
M5I_C9K7ITNS1-I-O>\ON;5OPNC-TOP1X@M-/N+&YU!)4-N\2.;Z9U8'&U#$P
MVKM`QO&6;J>IJJ-X*'-]GEOIO9IW7:R322T=[O8C$1=2$HQZJ7RNFK>>KNV]
M>AJ:AX:UF]U'57^U*+>YC=(]][*RL#MPIA(V1[<'YER3WZFBES0:<GL[[?WK
MK7I9:6V>[V#$1=2FX1ZIK[XM?.[=[[K8[*F6<_I'_(W^(_\`MW_]%F@#H*`"
M@`H`*`"@`H`*`//O&MA>0ZBMW;W=Z%D#2RK!+<[8HD"@L56[B7@DG"J2<C@D
M$FJ6E1*W5?B]-[_DUW[%OWDK;[?GZ?B_GV]`'W14F:V%H&%`!0!0A_Y&"\_Z
M]H?_`$*6@"_0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`!&1
MB@#S6VM[:P^*5M86UWO96:5K:>\NYY0/)P93NF*#[RJ-R=,X.1Q5&6DUY?=J
MM'^?1ZKI<=39-]?Q_P`EOY:>:/2JD1R-Z]\/'<!4:EL79CRQ(;4P^7)OW8^3
M?OV]?F^[CC-13<DY7VN_NLK6\^:_ROY#ET7I;UOK>W]W^;W>WO$5_ITUU?:Q
M?6UWJUE;/IY0/ON9,ROSN2`-D%`HX0*<N1U%4O<C)?WEY[:O7L[VTT5GTV3?
M,E;L_P#)?-:MIKMYFSX3-T?#=J+R.5)5+@&7S=SJ&.UB)69UR,':Q)&<'I6D
M[:6[+\B4N6ZO?^O/MM^*T);<W!U^7[0D:_Z.-NQB>-QZY`J"A-6\2Z1H4T<.
MI7T%J\J,\0EE5/,VD`JNXC+<C@41]Y\JWT_'_A@;Y=7MK^`]O$>AI;7-RVLV
M"P6LGDSR&Y0+$^<;6.<*V>,'FFES62Z[>?H!FZA!X(UK[1J&I1:%?_8CY$]Q
M<+#+Y!!^XS'.W!)X/K0DY6MUV\P*EMH'P]O;J\MK/0?#]S+9`>>L-I`YC))&
MUL#@_*>#4MVAS]"N5W4>K_X'^95M-,\`2V45QJ'A71M(,LJQ)%?6MJC.S#*@
M%2RDD'@`Y]JIJSY>IFI77-T_3^K[]BP-#^';3W,*:'X>8VC%;D_98!Y!"[CO
MR../Y'T-2FFN;IK^#L_Z_P"`5JY<BWTT]=OZ_P""3)X:^'TFEG4TT3PXVGA"
M_P!J%K`8MHZG?C&/?--^[N)-2V*<^D>`AI\%[IWA/1]6@F+;6L+.VD&U?O-D
MX!`[@$GT!H?NM*6G7Y=_Q&M4VON[OMV^^R\RS>>%_"%G/:+_`,(/ITT%PP4W
M$=A;[(B2`NX'#<D_P@^^*:7O<HKZ71!H^C>`];O-0M[/PIHKBQD\IY!;6KAF
MYR,*2RX(_C"^V:4=8*??^O37[^Z0-I2Y>H1Z%X+EU-+./P1I[1EBAN1I]OY2
MN,_*?XLD+G.W'(YHCK_6^E_R=QRT_K;I^>FFM^EM2R_A3P@LMY%%X)TV:6VC
M#[%T^!?-)SA5+8&>.I('/7K@Z7_K^OZ[!UM_7]?UW-;P[9Z5:Z:)-*T:'2DE
M8F2".&.,AP=I#;,J2,8R"1[TVK"1<U&^.GVOFK:S74A8*D$)4.Y/8;F5>F3R
M1TJ6[6125]S-U+Q39Z78Z;=302D:A*L4:&2*)E9@3@^8ZC/&,`D^@-4E>:@G
MO_P/GU[$.3C!R:VZ??\`+IWMYEB36V@U&XM9],NXH886F%TS1&-U7&<`.7'7
MNHZ&E'5?=^)3WLC5^E`!0`4`%`'G7Q%ATBPEM[Q]*\/-?71*B74M.%P\[C:J
M1K@JV22.><`=,"BD[5HI.VJVW]5Z?FUL4W[MYO1?@O3[W;RMNST1?NC(QQ01
M'8X^S\02?\)E?VUQJR>1")?.M'"*+5%\O8Y;`8;MS'YB0>V,&IHMSCJN_P!_
M,TE;S6O_``Z'.T7KI;\5:[>N]GI=62V>NH:I-JL>J:VUIK[06MO8,V;OR4@M
MYF^X0_EY`4*2=V[[Z\4XM*+N^J7GW:VMLTE_5R6ME'>S?Z+UN[O?2WF:_A/4
M)M3\-VMU/(\LA+J96=7$N&(WJRHBLIQD$*,@CBM)I*UNR_(E)JZ;O_7R_P"`
M]-=Q]M-.-7U"2X@6-UMH2%63=D!I>^!64I<L6^Q<5=I%.S\9Z?=0K,UMJ$4>
M(\E]/N!M+`GD&,84;?O_`'?<5JXV=EWM_78S4KQO_7_!^7ZE^;Q!8027T3+>
M-)8[/.6.QF<_/]TJ%0[QP>5SC!SBH^SS=+M?<7=7Y>NY6O?%FF65O+*!=3&-
M00(;.:3<2I88*H>PY/\`#D9QD9?*[I>OX:/T5^NPXKF?W?C^OEN&J^(&T[6=
M,T]8[5S>@G$EUY<I`*@^6FT^81G)&1@#-):R:[6_&_X::D-OE4EU_P"!^.NB
MZDLWB;3X(I7:.^/DSK;NHL9MVYFV@@%<LN?XAD<<&A:M)=?\KZ]OF-OE3;Z?
MU\_D20Z[9R7<-FQD$\N<%(9&B!!(P9-H4-QT)!],T+7[OTOIW_RU!NRN^[7Z
M:]OROHFR>35;>/5(].:.[,\B[@RVDK1`<]90NP'CH6]/44+6]N@WH/L[J2XD
MNDD@\KR9?+7+9+#:#GCIUZ<_T#Z)BUN9<&NWTCDR:9&L3R1^2Z7.[,3/MW,"
MHVM_LC=U'/7"A:25_P"KJZ_X/;S'.\6TOZMO_P`#OU2+VK:D=-@0QPB::0E4
M0OM!..,G!P,X&<=Z5];+^M4OU&K;O;^G^29"VJ7L?AZYOGT\&^MT?-K%(T@9
MESPK!-Q!QV3/MVIMJR:_K6S^X2OJGT_RNNW_``YFZ?XMEOM3T^R-BJ&>,M._
M^D!8F^;"`M"`6^7E7*,/0TTDV_+\]&_P?2[[I$W:2NM?TZ??]W9LUWU_1H]6
M&DOJUDNI'`%H;A!*<C(^3.>G/2DM=BVG%)OJ3Q74DFHW%LT&Q(D1E<MG?G.>
M.P&/Y\>K6UR=;^1C6/B>6[.JAK`(UG)Y<*AWS,<L!G<BXY7JN]>OS'!J')JE
MSVU_X%_R\O2Y?+^\Y>FG]=O36_=1->SOQ=LJF/8Q@CF'.>&SQ^&*TE'E;79_
MU^OW&<9<T5+O_7^1<J2@H`*`"@`/3'2@#B;6R6T\7P)<ZGK5V/M)9))TM!;O
M<>21M^1%D!$>3G`7CKG@U2;LTET?W75[?/OY^13N[M;:7^_3]._3L=M4DA0`
M4`%`%`?\C`__`%[+_P"A&@"6XL(KEW=V<%X6A."/NMU_'BA:7^7X7_S#JGV_
M6W^1AQ^#5CM]2B&OZNYOYA*SS2QRF(`D^6@="HCY(VD'BG%N*BOY7?UTZ_GI
M9W)<$W)O9JUNG].]GY%C3/"T>FS7DKZKJ5\]S<+<9O)Q)Y>"2$3@;4R3Q0G9
M)=K_`(JP.-VW?>WX._\`PY:L-%%A+=L;^ZN$G&U(Y1'MA7+':NU02/F/WBQX
M'-2XIT^3Y?+;\#3F][F7]=S,N?`]A)I5OIEC>WVE6<$JR^5I\JPJ^!@JP"X*
MMU([GFK4FIJ?;IT[_P!>IDX7@X7W5K]?6_?_`"1HW&@17$MS(;RY0S/YBA=G
M[IM@7*Y7V!PV1D>G%1LK?UNG^:_$O2]W_P`/HU^3M\EUO>>WTI(M+>QFNKF?
MS=WF3F3RY7)ZG=&%VG_=Q3=K67]=?S_JPEHVRO-X>A:QM[2"^OH%A8_O//,T
MCJWWD9Y=YP?KD8&"*'JTWZ?U]Q2=EI_PS[_UH+=:))<ZE9WBZM>P"U8E8(Q$
M8V!V\$,A/0$9!#`,V#S51E9WW_I_UVT5R4K1Y5_7];^ORM+IVD+IUQ<2B[N)
M_-/R)+LQ"N2=B[5!QDG[V3[U*5E;^M-ON&]97_KS?S^[LD5[30?(O%N#>SA4
M+8@7;Y;')VN<KNW!3CKCCIGFE%<JLNWZ)7^Y#;O_`%YWM\GVU[L270)Y9;UV
MU[4@+JV^SX3R5\KC[Z$1@AN2>21ECQTQ5]&K=;_\#T]11;C;K;^OZZ?(LQ:+
M;'1%TG4,:G;!=K"[AC(<`Y`*JJIQQC"CH*)-2=V@BW'9C&T"RBTI=/TQ%TF-
M'WQ-8Q1IY39Y*J5*\\YR#UJ7K;R_K]1JROIO_7]?Y#+S0C=6262ZI>V]J$$;
MQQ>7^]7!!!9D+#=GD@@^A%5>TE+MTZ=/RM^+O?2RBW%\R>OZZZ_/[M-M[V;K
M3Q)#>^4V)KF+RMS'A1@@8_,G\:EJZL]F_P#*XXOE::Z%U5"(%'0#`JF[NY*5
ME9"TAA0`4`<3XQL0)WN)]4UK[/);R+-#9I:%(+?"^8Q\Q-Q7@$@%F]!54FU4
M22OJO2]]%W[_`*O8TCS-Q4-^G>_]>AVJXVC'3%2S*-K*PM`PH`*`,^-0^NWJ
ML,@VL(/_`'U+2:35F-.SNBGK'A#0M>BM8M3L?/2T='A'FNNUDSM/RD9QN/7U
MJU)J?M.IFX1E3]D]MA-3\':)K%KJ%KJ%O/<6^H.DEQ$]W-L9EQ@@;L+T'W<9
MP,U%DDEV;?W_`/#[;&E];DUQX9TNXL$LFBGC@0@J(+J6)ON[<;D8$C``QG!J
M^9N7.]]?Q=W^)-.*IQY8[:?@K+\"_-8VUPX:6/<R@*#DC`!##]0#^%3L[_UI
M_P`.PLK6_K4RK+P;H6FIJ"V=F\']H7`NKADN)`SRAMP8'=E>?3`IQ?*E%;+8
M3BG*4GNU9_C]V[U6J+::#I\>H1WJ1RK*F<*+B3RR3GDQ[MI/)Y(R/PI+W=OZ
MTM^6A3UT?K^OYZVV)9-&TN75(]4DTVT?48EVI=-"IE4<\!\9`Y/?N:$^6]NH
M/7<CM=$L[*>YFA>[WW,HED\R\F<;@<C`9B%';`P"`!C`%-.R2[?U_7W[BDN;
M?^NO]?<5IO"FE3I*C"\022B9O*OYXR&&2`"K@A022%&%!YQFE'W+6Z%-WW_K
M_A^O?J7K_38=06-)B=B[@P#$$J5((!!!!Y!R.012LKW_`*W3_-($[?U_5]+D
M:Z-:)8"R1KE(?+,>5NY0Y!.22X;<6S_%G=UYY--^\K/R_#^M>_4E*SO_`%_7
M;MT(K7PWIEE<P7$$4RR0*57-S(RMDDEF4MAWRS'>P+<GFG=_U]WY:#E[UK_U
M_FET3T70U:0&<-$LQJ-S?A[OS[F/RW_TR;8%_P!E-VU3[J`>3ZFFGRJR[W_K
M_+84ES*S*Q\)Z&\-Q!<6"WD%PP9XKQVN$&"2`JR$A`,G`7`%1RII*VW_``V^
MY5VI<W]=]B[8Z7;:<P6UC2&!(4@BB1<+&BYP!^?Z5=[WN2E9)+I_7^1=I#"@
M`H`*`"@#CM%M9+WQC?:PL=M&C8VFYT]3<M$5VCRYEE.(RR%MK*#UX&0:*37)
MS6W^3Z/7OII\EV*J6NDNFGS6_P"=NWJ=C02%`!0`4`4!_P`C`_\`U[+_`.A&
M@"_0`4`%`!0!S-M::U%K^KWT40:,_+`D^H3;)3M7`\LH5B`(;YDR3GD4E=0T
MW_X+Z^FRV?D2U>?E_P`!:6V>O7=;=66+[5=3MK35'6R<O9P,Z>5;M.96(RH1
M<KOQR",C)QR,T-Z-KO;^OE;7;?L4M[>5_P"OG?Y6[F78^(=6_LV'4;O3KQ7N
M8U4Q&QE#(^'QF)2Q3)"YR2!GD]ZJ2Y4TM^GK:.GIO\R:;<W=Z+KTTO)7_+Y:
MVMM>TO5->N?%^H65Y:V\6E11*T#+#.)"V%SEROE,.3PK9&.1UPXI.,F][_AK
M_P`#;0;;3CYK7U_3M9ZO?8ETVY\0SR:LE];>4J9%FQ@2/=]['(GDW?P]53Z=
MAG+^%?[7_`_KJ6K<ZOL4;)S'X<NUM_[8,,K83[0MP9P`H\S:7_>#HVWW^[U%
M5/96VO\`A=?/OYV%&ZG_`'G]W-K_`-NVV_N_>0)')NTM5;6O+W$V>XW&0/,R
M?/SVV8QYW/7^*A7Y]>R]+:W\KVMYW^8FER-+;\;V5O.U[_W>^EB&>.1M)U8&
M?6(79D$SM%>RXFWG/E+&ROLQC_5D)C'O41^"-_+UVU_X%[J^Q;LIMOS^[[/E
MZVU[ZG8::TS:7:&X1DG,*[U9MQ#8&03@9/X"MIVYG8S5EHBU4#"@`H`*`"@`
MH`*`/./&<^@7OC#3K?6=4LM-:Q4^5-+<6QD#/AL^5-$X"_NP`X(.>,=Z*$N:
MH[+5-*W=Z/IJM_ZT+G94^5]=?S7_``Z]&>CCIUS09K8*!A0`4`4(?^1@O/\`
MKVA_]"EH`OT`%`!0`4`<KH_AS4-,34);:;3[.XO)RY,=CCY=['+XD^>0@_?X
MQW4TM5",5T2_+IV=]WK>VPK>^Y>OY]>Z[+2UWJ1ZU-XM&DV4NG64TE])=KYT
M4,\$8BB`P<F16W*2,X7#?-U&*J-G.-]%U^_\TM---.I,G)4Y6U:VZ7_17?X6
M\RZ?[8LA:6]M9RR)(S^8R-%B+]YNW-N8$@KD?*#]!4QZ)]H_@M2K63?G+\=G
M\OU*FF0>+&C\0+?7DC222-_9^Z*&%8ASC:ZF0L/N\O'GV/2A?PH_S=?P_P"#
M_P``J7\1VVM_7G?OT[:$L^GZC+X4AM]9L_[8G63=<6OF12^>NXX&62)#CY3R
MJ_=[GDNI9N+2_JS\^_\`PP0NKZV_K]5=?/70IZ]H]_=Z%IMA:Z<DDL!0#SH8
MYXH25(WX,J$%,###)&>%/:DKU%*3^?W:]=7TT?6XH-13BEIVZ6N]&NRTTVVL
M]"*YT"]?6]<NC933M/:M$DLD-JRRKA<1J<K(02"&5V"GL1G(S2M!KN[OSUT\
MFK:.^O1:#5XSB[[+ITT^].^JMIWU.A\,65SI_AZUM[J**&5=Q\F&(1)$"Q(0
M(&8+@$#`8CC@XK6=KV7]?E\B4:]0,*`"@`H`*`"@`H`*`"@#*MO"_A^RU#^T
M+70M.@O<EOM$5JBR9.<G<!GG)S]:(^XN6.BV^0/75FK0!R-[I-Y)X[@U%=+,
MBQ[&6^#H/+C$<@:'!.[EF!QC:<Y)R!44^:+DV^K^:LDE\I)O_AQRL[+TMY.]
MV_*ZTNKM[-6*^J>&#>7FKZK;:+!#<SV(@"`1I+<EB&E#L#@\*J#)Q][G!S3L
MXQ<8[<T7TLTG=OYW=[]D*\I)6T=GK?9M66JU7+W3Z[72-SPM8R:?HBP/9?85
M\Z5XK7*GR$9R53Y25&`1P"0.@Z5>MDF[O^M/DM/.PM+MQ5E\NVNW=W?SUU%-
MIJ?]LO*MW&$,(`;[/Q]X\?>ZTAEK[/J?_00A_P#`;_[*@"&ZCU>&SFEAO(I9
M41F1!;_>('`^]WH`F^SZG_T$(?\`P&_^RH`/L^I_]!"'_P`!O_LJ`(5CU<WC
MQ&\B$2HK!_L_4DG(^]VP/SH`F^SZG_T$(?\`P&_^RH`CN(M6BMI7CO8I'5"5
M06WWB!P/O4`/6#5"BDW\()'(^S=/_'J`%^SZG_T$(?\`P&_^RH`A6/5S=R1&
M\B$2HK*_V?[Q);(^]VP/SH`F^SZG_P!!"'_P&_\`LJ`(KF/5XK6:2*\BDD1"
MRH+;[Q`X'WJ`)!;ZH0";^$'_`*]O_LJ`%^SZG_T$(?\`P&_^RH`B$>KF[:(W
MD0B"!@_V?J<G(^][#\Z`)?L^I_\`00A_\!O_`+*@"&ZCU>&SFEAO(I941F1!
M;_>('`^]WH`F^SZG_P!!"'_P&_\`LJ`#[/J?_00A_P#`;_[*@!UI]N2\FBN7
M66((K(ZQ[.26R.I]!^=`%V@`H`XZSGO(?&5_-,NJ>4@E,P9)7MRG[ORO+'*E
MOO9V<_>W=JFCS./O6Z^M^9V^7+OTV\PG9/7Y>EM=NO-M?WNV@S6=/ODU'6KZ
MQ;5%C2RV%$N9F$KN06,498A2J+P4`.7/<4D^6+2_FCWO:]Y.^]FGTVMH-MNW
M+O9OIO:T5KIOO=6VUW-KPMYW]AKYGVO9YTOD?;-_G>5O.S=O^?IC[W.,9YK3
M6RYK7\OP^=K7\[D^[=\NWS[:[^=_+MI82-=5&M73`6H)@B&3NQC=)^O_`-:D
M,N?\3?\`Z<__`!Z@"&YGU>V@\S9:/\RK@;L\D#^M`$W_`!-_^G/_`,>H`/\`
MB;_].?\`X]0!#;SZO/YOR6B^7(4YW<X[T`3?\3?_`*<__'J`(99]7CN((MEH
M?-)&1NPN!GF@";_B;_\`3G_X]0`A.K@$XL^/]Z@".UFU>YM(9]EHGF('VG=D
M9&<4`2_\3?\`Z<__`!Z@"%9]7-X]OLM!LC5]WS8.21C_`,=_6@";_B;_`/3G
M_P"/4`0W4^KVUN9=EH^"!M7=GD@?UH`F_P")O_TY_P#CU`!_Q-_^G/\`\>H`
MA@GU>8S#9:+Y<A3G=SP.?UH`F_XF_P#TY_\`CU`#1/J,5W;1W"0-',Q4F/=E
M<*3GGZ8_&@#1H`*`"@`H`*`"@`H`JQZE8S:A-I\5[;O>P*&EMUE4R1@]"RYR
M`?>A:JZ!Z-)]=46J`(;JZM[&UDNKN>.WMXAN>65PJH/4D\`4FU'5C2;V'03P
MW5O'<6\J302J'22-@RNI&001U%4TXNSW$G?8DI`4)=<TBWAAFFU2SCBFE,$3
MO.H#R`D%`<\MD$8'.0:+:I=P>EV^A?H`BEN8(988I9XXY)V*Q*S`%R`20H[G
M`)X[`TTF]@VU(K34]/OY;B*SOK>YDMG\N9(95<Q-Z,`>#QT-):JZV!Z/E>Y9
M9@BEF("@9)/04FTE=@E?1%&+7-(GTS^TX=4LY+#.W[2DZF+.<8W9QUX^M59Z
M+N&]_+_A_P`B_2`J7.JZ=9WEO9W5_;075R2((9)55Y2.NU2<M^%"U=D)M15V
M+:ZE8WTMQ%9WMO<26S^7,L4JN8F_NL`>#[&A:JZV&]'RO?\`SV^\LLP12S$!
M0,DGH*3:2NP2OHC-'B30FTLZH-:L#IX;9]J%RGE;O3?G&?;-59W2ZO;S].XD
MT[VZ;^1I_2D,AN+NVM/*%S<10^=((H_,<+O<]%&>IX/%"U=D&ROT7_#?F1V6
MIV&I&<6-];W1@<QR^3*K^6XZJV#P?8T+576P;.Q:H`SY]>T>UA,UQJUE%$LQ
MMR[W"*!*/X,D_>]NM"ULEUV\P>E[]-_+U-"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`YNPT34(/%,U
M[-]E^QJTSQ.CL97,GEY#`K@`;.Q.>.!BIIQY(V;=]?363E]ZO9?/N#ZI=6G]
MT>7Y][Z6VL]SI*H#%\4:3<:QHXM[;!E2:.4(;F2W#[6!QYD>67UR!U`J6FY1
MDNE_Q37ZW"R:<7Y=+[-/]-^FY?TJVFLM)M+6XF:::*)4>1G+EB!R=QY/U/)[
MUI)W?]+\%HO1:"5[:_Y_+Y%IAE2,`\=#T-0U=6*6C.'70?$@\*_V0;'2=DMY
M*]Q"MZX1X'=G\L-Y/'+;3\OW0<$$C&WM/?A)]$OO5K/S[[K6VZN$VI*72Z2_
M"S_KS\CN!]T9`!]!61*V,+7-.U"[UK0[NQMK-X[*X:29YIF1PI1DPH"-G[Y/
M)'W0.^1=.7*Y7ZJWXW_3\?OOFM!KO_FG^A1\)>'-2T75=7NK^=)%NF'E`3M+
M@!Y&X!5?+7YP!&"P&#R223,7:DH/=?Y)?I?RO;;:9/FG?IK_`%;H^[^UUV.J
M?>(V\L*7P=H8X!/;)J)7L^7<:M?4X2X\*>)-1\-W%O+<:9::E<2R2W!P]Q%<
M,R!0<XC*;1P!AL!1G<>:U;M.$HO2/3YWO?[[[;M:*Q$XJ49K^;SZ6M;\M>^M
MCNT#+&H<@L!R0,`FI>^@TFE9F%K^E7^IWVF&U$20V\RRO,]TX*X8$CR0I23(
M&`6(VDY'(I0?+4YGM_FFOZ?J4[.#BU>_])_+>VSLB+PWHFH:9?7,U[]E"",0
M0F!V9I%$DC[GRHP?GZ#/<YYJ:<>2FHMMNR7E[JM?U?7Y">]EM>3_`/`G?;RM
MO?7LCHGW!&*`%\<`G`)^O:B5[.VXU:^IP,W@S69M.4"1(KC[6\RQIJMP#$&C
MV;OM`422,",X88P=N<`52T<;.UDU]\D[V>CM;KWU"5I-RLKWOZNS6_V=';1.
MR6VNG?("J*K-N(&"3WIO5Z$I65CGO$>A:KJM_I\]E?VL4-M+&[PSV[.3MD5B
M58,,'"XY!_#)I4[PJ<[V_P"`T_ONON3\A58\]/D7]6:?X:^M[>:ET*QU2'5-
M4O=6@M!-<NHCEMYV<^4I;8A4QKMP"3U;)9N@P!2E^[47H]WZZ7?X6V6B76Y4
MDG.ZVV_K^O+H;4Z2/;R)#)Y4K*0C[=VTXX..]933E%J+L^_8<6DTV><ZAX"\
M17&BS6(U*SDDDNFD#PM):94P"/+?ZS<,C)0\-W;J*VC*TX/HO_DE*WI;3YZ:
MJY$4XN3[M/>ST5M[>Z_->?>QZ2HVHJ\<#'`Q4O<:5E86D,*`"@`H`Y+3-(NX
M?'-YJ#Z;Y*MYN^^WI_I*MY?EI@'=\NUOO``=LY-324HP:D^^G?WFT_E'3Y^0
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MLXM$N8TN]2CGC+_9IS-&%C5BJ/(5)S&3B3&`0<$C;1/WJ<$NE_E\33\]6KZW
MWZZFKDD[KM;\?\O\GH=GX=M;BQ\-:7:7:!+F"UCCD56R`P4`C.3W]S6M:2E4
MDX[7,(*T;?Y+\%HO1:+IH9?C>PDU+3+:VCT-M3W3@L\?E>9;*`<O&9'7#]@P
M.5SGG&#G3:56+?36_P`UH_+OH[I6ZW*DKPDK[_U^'YC+/3=97Q])J=U9VHLF
MMI(4N([@F0+N0HC(5&.CGAB.3TX%%.\824MVU^#=OP:OY[;NT33<H-;)/\;?
MJONWVUZ>7_4OF,R#:?D&/F]N>/SJ)_"]+_UYFBW/,#X3OT\.FS3PXTML;J9X
M;20VT<D3-%M25A&1$NU\X\OD`@X+9IOG;A:5K)J^]GS)I_)7_+8/<4G)+1M-
MKNK--);-?#I)]+M['I\2LD**[;G"@$^IJI--MHB*:23.4U?1;JZ\;6FHV5@T
M<L4#QO>NL`0`HP`##]\6#$<'Y,9.,X-9>]RU%'1M-+UTL_\`A^QI[CY>97L[
M_IK\K[=7KY2>`M(N]&T::&[MY(&DF\S;,D`D+;%#,QA`5LL#AC\Q'6MY-626
MRV79=%;;[M-NMS**:T?W[W?=-ZV]==S3\26NH7NBRVNG0VT[RD+)%<2F-7C_
M`(EW!6QD<=.A-85%)I);=?N=OQL;4Y<KOU_K^O4YO1](OHM;\//>^'?(DL=/
M2*2^@>)B7V%3&[;@Y1?0*P+,#QMR>ISBYU)+K]SV?W]%>VB?=6YJ=-QI4XO=
M?\-_P7;\=3NZQ-C@-<T/Q%>:QJ]PNGVDL5QI\UM#-'.&D()38AC=57/#G!;:
M23D@&IA=0:FMW%Z=DWW_`+MO*_1W8-M5(R6R3^]I=O-;K6W:ROO>"=-NM(\*
M6ME>0>1+&\I\LJBD*9&*Y5"44X(X4[1VXK6;O;T7WVU)BK7_`.`ORT_5[O5L
MZ&H*"@`H`*`"@`H`*`"@`H`X[Q=X@O\`P_KFG74<K'2XK>:2\MDAWM+\R(A!
M'(PSCIV)H5_>LKO1+IJ[V^]JVMM[]")NSBMMV_16O]R;??3J55\5:GH?AN&7
M4WM+J^:ZFA>2ZN!:Q94D[%8(V6XPHQDXY.>N4:BLE9OXME=OEE;1:7DUTTZF
MMK\TGIMZ*Z3U>FBVO;MIJ1O\0-0DT8ZBFE6EE&3`Z?;KMH]L;RF-O-^3]VP(
M_P!H=^V#O!*52-/TOZ23:MW=U:VG2SUTQ4G*#E%=U_X"TG\M;WZ;B?\`"=ZA
MIFC7EUJ5K8GR&W1S27WEJ\9F=,M^[^4@)PJARW;FLXRBY0AU?+?YQ;5NK;L]
M+:=[7LZ=Y)M:ZR7W2MZ65]^MNYM^+]9N=/TF!+&6>*]N2?+:"T>Y9=JEN456
M."0%)QQN[&B4N6=M[7=N]NE^FZU-(6E&[V>GW_Y*[6GJC`O?&>JK.^KV9LQI
M/V6S=%N[GRH\3O@NY\HLI`!'WB!U()Z=$:?O\CUO*UUV4;Z=[W5N^R:ZY2G*
MRBHOF2N]-;WM;?I9MO2WFBYIOCZ[U-M3CCT>WCEM;M+6%6U*-BY9BH,BH&:+
MD=&7/UQ65)>TA";TYK_*RYOO\NC*JR]DW?;3\6E]VNCZH=J^MZE8^.4A%Q<I
MIT<46Y`D1@+/YO#':90QVKMQ\N1@\D`PY.,'*U]_N44]+=;[WZ7MK8+MR4?)
M?*\K:WZ=%;6^^FI7TSXBWFJ>&EU.'1;87)EEC,`U)9(\1Q^82)41@?ESP!UX
M..<74M2CS2VLV_D[:=_O1,*G//DZN22^<>;7L27/CF=-<NHH8[3[+902/)$;
ML>:6`0J9%V?ND^8G=DY`)Q6#FXRU6FJ^:FHW;\KW]'<V5I)6\O7X6[)=>G;7
M0F7QO>RVEM+;:993M(27:._)A*"58]T;B/YQE@>B]_3G1RLKV?1:Z:MM+Y75
M[]FG;H9<ZYN7R;_\!2;^>MO5,AN?'DEEI6H:E-;P(]NT4)@GO!'")#(\9"R>
M7GJO5AC')V\U:2]S7XG^'*I?.U]M][-Z(B-3FG-6^%?^W27Z?EMJRK'\2;NZ
MT_5;B+3].MSI][#`7FU(-$T;R%"[,J_NSQ]UAD9Y'8U2CS^S?\S:\]K_`#>M
MK::Z;E2DU*4$M4D^_6S^22O?MKMO>M/&\G]H0V)MX9"QD)\R[`N"`S_,D8C`
M9!L`+9&/<CG!U+1;L]$O_25*[[)WM?\`FTLBH/F5WUDU_P"3..G>UKVZ+JS<
M\.ZW/K4$[W-G':O&R%5CF,H9'174DE5P<-R,''J:U:2;BMXMI^JMMY:KL*$^
M>,9K9I-?._\`D;5(L*`"@`H`*`"@`H`*`"@`H`*`/,HO%'B#SI=/>])G%^UP
MLXME`%F)_*$6<;=V[C/7;[\U+=E#_MV_GS6MITT<MNL=];$*5^?_`+>MY<M[
M^NRW_FW=K&U!XXN+J2[BM]/LY98YDAC5+XG:S.4"S8C_`'3<`[?FX)].53E[
M2,6E:ZOY;-VOW5K-=+K74JK*-)M/_@ZM)?)WT?5(HW'C76;B\@MK.VTZ*2:*
MTGCADO")'WR;74_NS\G&-X&1QQ\W&E.TXJ<=K_AR<ROV?WIV:OIK%9NGIMLK
MVZ\_*TN^F_5)W-G1O%YU77(-,>VMH'EL5N\+=>9(#D!AL"\*"1AF*D]EZXFG
M*-2+G'96^YI-7[/7;5Z-[6;TDG%V?FON;6G7IOM\RE/XKN(O&,MG$\KV[+);
M1126SI`TZIY@/G[".<.I`)QMZ=:E2O3DUYM?)V:MUZORL7RKFBM>E_1]7^"6
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MC\1+NPTN.YN+:QO))9)G5(;[_6HKX"6_[O\`?MMYQ\O;GFHC4:34D[KR_O26
MW96]Y]%K;H6TM7Z>FRZ]VWHNKNNAJV/C"^NID2YTN"WBF!"2179D8$P^:N5,
M8`^7.>3@XZCFM9Z>T2^Q?[U;;[UKZZ=\H5%)4Y+:=OQO_D93_$J2VT;4KB.S
ML[N73EM@5?4TB9S(H)\PLBK'@$<_=)X!SP*J-1?_`&])::[7_P`FK/7UTNJ,
MG.$6^L4_OM_GO_2MV/C:ZO[>[FD@AC$-S;".&UN`\^R5%;YU9.,Y(!'7D#&,
MEU5[*-WK;GV_NJ3^_1:>CNT[$1J.45*UK\O_`),XI^J3;UMY;ZBP^/;JXTIK
MJVTZPN9=S;?(U$O"56/S&_>"+[P`(*[>#CGGB)2C!.4KVBFWZ*VL>ZUWTU37
M0VNN=06[:7HVF]>STVUW1VT4@EA20`@.H8`^]5)<K:%%\R3'TB@H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`_
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
